GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 11:25:55 ; Search time 1696.36 Seconds
(without alignments)
95.477 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggacttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 27472414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	12	100.0	125	9	AV744760	AV744760 AV744760
	2	12	100.0	135	9	AW168558	AW168558 xi89a04.x
	3	12	100.0	139	12	AZ727644	AZ727644 RPCI-24-1
c	4	12	100.0	144	10	BF757323	BF757323 MR0-CT045
	5	12	100.0	178	9	AA887620	AA887620 nq96a01.s
c	6	12	100.0	183	10	BE666630	BE666630 150209 MA
c	7	12	100.0	183	10	BE667317	BE667317 151609 MA
	8	12	100.0	186	12	BH218996	BH218996 1006083F1
	9	12	100.0	187	9	AA917080	AA917080 ol47g07.s
c	10	12	100.0	190	9	AW703817	AW703817 sk13b08.y
c	11	12	100.0	191	9	BE083238	BE083238 RC3-BT064
c	12	12	100.0	191	9	AA613566	AA613566 nq22f06.s
	13	12	100.0	192	9	AW873686	AW873686 hq28e02.x
	14	12	100.0	198	9	AV357824	AV357824 AV357824
c	15	12	100.0	201	9	AI382447	AI382447 ta72e07.x
	16	12	100.0	204	10	BF154634	BF154634 RC2-BN040
c	17	12	100.0	205	10	D77250	D77250 MUSA0A05 mo
	18	12	100.0	209	9	AA373341	AA373341 EST85505
	19	12	100.0	218	9	AW084153	AW084153 xc48a07.x
c	20	12	100.0	222	9	AA593275	AA593275 nn08d10.s
	21	12	100.0	223	9	BB015270	BB015270 BB015270
c	22	12	100.0	224	9	BB062601	BB062601 BB062601
	23	12	100.0	226	9	BB468472	BB468472 BB468472
	24	12	100.0	229	9	AI649331	AI649331 uk26d07.x
	25	12	100.0	232	9	BB015909	BB015909 BB015909
	26	12	100.0	234	12	AZ060612	AZ060612 RPCI-23-4
c	27	12	100.0	237	9	AW703816	AW703816 sk13b07.y
c	28	12	100.0	237	9	BB512831	BB512831 BB512831
c	29	12	100.0	237	9	BB604122	BB604122 BB604122
	30	12	100.0	239	9	AV646685	AV646685 AV646685
	31	12	100.0	239	9	AW836013	AW836013 PM0-LT001
	32	12	100.0	243	9	AA578485	AA578485 nl66e07.s
c	33	12	100.0	246	12	AZ062841	AZ062841 RPCI-23-4
c	34	12	100.0	247	9	BB606343	BB606343 BB606343
c	35	12	100.0	248	9	AA963640	AA963640 UI-R-E1-g
	36	12	100.0	248	9	AV277719	AV277719 AV277719
c	37	12	100.0	249	9	AA569798	AA569798 nm41f11.s
	38	12	100.0	250	9	AI538725	AI538725 tp57f07.x
c	39	12	100.0	250	9	AA344448	AA344448 EST50340
	40	12	100.0	251	9	AW534853	AW534853 UI-R-BS0-
	41	12	100.0	251	9	BB289766	BB289766 BB289766
	42	12	100.0	252	9	BB387551	BB387551 BB387551
c	43	12	100.0	253	9	BB010631	BB010631 BB010631
c	44	12	100.0	254	9	AI594640	AI594640 vt51b03.x
	45	12	100.0	254	9	BB282512	BB282512 BB282512

ALIGNMENTS

RESULT 1
AV744760
LOCUS AV744760 125 bp mRNA linear EST 17-OCT-2000
DEFINITION AV744760 CB Homo sapiens cDNA clone CBCBJG08 5', mRNA sequence.
ACCESSION AV744760
VERSION AV744760.1 GI:10862341
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 125)
AUTHORS Zhang,Q., Ye,M., Wu,X., Gu,J., Huang,Q., Zhou,J., Shen,Y., Han,Z., Chen,S., Mao,M. and Chen,Z.
TITLE Homo sapiens CB library cDNA clones
JOURNAL Unpublished (2000)
COMMENT Contact: Zhu Chen
Shanghai Institute of Hematology, Rui-Jin Hospital
197 Rui-Jin II Road, Shanghai 200025, P. R. China
Tel: 86-21-64740490
Fax: 86-21-64743206
Email: mbshi@ms.stn.sh.cn
This clone is available at Shanghai Hematology Institute in Shanghai.
Chinese National Human Genome Center at Shanghai
351 Guo Shoujing Road, Zhangjiang Hi- Tech Park, Pudong.
FEATURES Location/Qualifiers
source 1. .125
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="CBCBJG08"
/clone_lib="CB"
/tissue_type="cord blood"
/cell_type="CD34+ hematopoietic stem/progenitor cell"
/lab_host="BM25.8"
/note="Vector: pBluescript; Site_1: EcoRI; The insert is cloned randomly with the EcoRI digestion"
BASE COUNT 17 a 30 c 39 g 37 t 2 others
ORIGIN

```
  Query Match             100.0%;  Score 12;  DB 9;  Length 125;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     45 GGGGACTTTCCC 56


RESULT   2
AW168558
LOCUS       AW168558                 135 bp    mRNA    linear   EST 12-NOV-1999
DEFINITION  xi89a04.x1 NCI_CGAP_Mel3 Homo sapiens cDNA clone IMAGE:2652942 3',
            mRNA sequence.
ACCESSION   AW168558
VERSION     AW168558.1  GI:6400083
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 135)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Robert Sikorski, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: Life Technologies, Inc.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found
            Seq primer: -40UP from Gibco.
FEATURES             Location/Qualifiers
     source          1. .135
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2652942"
                     /clone_lib="NCI_CGAP_Mel3"
                     /tissue_type="metastatic melanoma to bowel"
                     /lab_host="DH10B"
                     /note="Organ: bowel (skin primary); Vector: pCMV-SPORT4;
                     Site_1: SalI; Site_2: NotI; Cloned unidirectionally.
                     Primer: Oligo dT.  Average insert size 0.9 kb. Life
                     Technologies catalog #: 10981-017"
BASE COUNT       21 a     58 c     26 g     30 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 9;  Length 135;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     27 GGGGACTTTCCC 38


RESULT   3
AZ727644
LOCUS       AZ727644                 139 bp    DNA     linear   GSS 25-JAN-2001
DEFINITION  RPCI-24-113M16.TV RPCI-24 Mus musculus genomic clone RPCI-24-113M16
            , DNA sequence.
ACCESSION   AZ727644
VERSION     AZ727644.1  GI:12485140
KEYWORDS    GSS.
SOURCE      house mouse.
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 139)
  AUTHORS   Zhao,S., Nierman,W., Malek,J., Shatsman,S., Akinret,B., Levins,M.,
            Tsegaye,G., Geer,K., Krol,M., Shvartsbeyn,A., Gebregeorgis,E.,
            Russell,D., de Jong,P. and Fraser,C.M.
  TITLE     Mouse BAC End Sequences from Library RPCI-24
  JOURNAL   Unpublished (1999)
COMMENT     Other_GSSs: RPCI-24-113M16.TJ
            Contact: Shaying Zhao
            Department of Eukaryotic Genomics
            The Institute for Genomic Research
            9712 Medical Center Dr., Rockville, MD 20850, USA
            Tel: 301 838 0200
            Fax: 301 838 0208
            Email: szhao@tigr.org
            Clones are derived from the mouse BAC library RPCI-24. For BAC
            library availability, please contact Pieter de Jong
            (pdejong@mail.cho.org). Clones may be purchased from BACPAC
            Resources (http://www.chori.org/bacpac/orderingframe.htm). BAC end
            page: http://ww .tigr.org/tdb/bac_ends/mouse/bac_end_intro.html
            Plate: 113  row: M  column: 16
            Seq primer: T7
            Class: BAC ends.
FEATURES             Location/Qualifiers
     source          1. .139
                     /organism="Mus musculus"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="RPCI-24-113M16"
                     /clone_lib="RPCI-24"
                     /sex="Male"
                     /cell_type="Spleen/Brain"
                     /note="Vector: pTARBAC1; Site_1: BamH1; Site_2: BamH1;
                     RPCI-24 Mouse BAC Library produced by Pieter de Jong. The
                     library was  cloned in the pTARBAC1 cloning vector at the
                     BamH1 sites using MboI  partially digested male C57BL/6J
                     DNA."
BASE COUNT       38 a     31 c     34 g     36 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 12;  Length 139;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    120 GGGGACTTTCCC 131


RESULT   4
BF757323/c
LOCUS       BF757323                 144 bp    mRNA    linear   EST 12-JAN-2001
DEFINITION  MR0-CT0452-041100-303-a05 CT0452 Homo sapiens cDNA, mRNA sequence.
ACCESSION   BF757323
VERSION     BF757323.1  GI:12105223
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 144)
  AUTHORS   Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
            Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
            Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
            Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
            ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
            Simpson,A.J.
  TITLE     Shotgun sequencing of the human transcriptome with ORF expressed
            sequence tags
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
  MEDLINE   20202663
COMMENT     Contact: Simpson A.J.G.
            Laboratory of Cancer Genetics
```

```
            Ludwig Institute for Cancer Research
            Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
            Brazil
            Tel: +55-11-2704922
            Fax: +55-11-2707001
            Email: asimpson@ludwig.org.br
            This sequence was derived from the FAPESP/LICR Human Cancer Genome
            Project. This entry can be seen in the following URL
            (http://www.ludwig.org.br/scripts/gethtml2.pl?t1=MR0&t2=MR0-CT0452-
            041100-303-a05&t3=2000-11-04&t4=1)
            Seq primer: puc 18 forward
            High quality sequence stop: 143.
FEATURES              Location/Qualifiers
     source           1. .144
                      /organism="Homo sapiens"
                      /db_xref="taxon:9606"
                      /clone_lib="CT0452"
                      /dev_stage="Adult"
                      /note="Organ: colon; Vector: puc18; Site_1: SmaI; Site_2:
                      SmaI; A mini-library was made by cloning products derived
                      from  ORESTES PCR (U.S. Letters Patent application No. 196
                      ,716 -  Ludwig Institute for Cancer Research) profiles
                      into  the pUC 18 vector. Reverse transcription of tissue
                      mRNA and cDNA amplification were performed under low
                      stringency conditions."
BASE COUNT       32 a     28 c     53 g     30 t      1 others
ORIGIN


  Query Match             100.0%;  Score 12;  DB 10;  Length 144;
  Best Local Similarity   100.0%;  Pred. No. 5.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db      78 GGGGACTTTCCC 67


RESULT   5
AA887620
LOCUS       AA887620                 178 bp    mRNA    linear   EST 07-APR-1998
DEFINITION  nq96a01.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1160136 3',
            mRNA sequence.
ACCESSION   AA887620
VERSION     AA887620.1  GI:3003295
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 178)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Ilan Kirsch, M.D., Michael R. Emmert-Buck, M.D.
            , Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html
            Insert Length: 886   Std Error: 0.00
            Seq primer: -40m13 fwd. ET from Amersham
            High quality sequence stop: 169.
FEATURES              Location/Qualifiers
     source           1. .178
                      /organism="Homo sapiens"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:1160136"
                      /clone_lib="NCI_CGAP_Co10"
                      /tissue_type="colon tumor RER+"
                      /lab_host="DH10B"
                      /note="Organ: colon; Vector: pT7T3D-Pac (Pharmacia) with a
                      modified polylinker; 1st strand cDNA was prepared from
                      RER+ colon tumor, and was then primed with a Not I -
                      oligo(dT) primer. Double-stranded cDNA was ligated to Eco
                      RI adaptors (Pharmacia), digested with Not I and cloned
                      into the Not I and Eco RI sites of the modified pT7T3
                      vector.  Library is normalized. Library was constructed by
                      Bento Soares and M. Fatima Bonaldo (N-Soares4). "
BASE COUNT       50 a     51 c     38 g     39 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 9;  Length 178;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db      68 GGGGACTTTCCC 79


RESULT   6
BE666630/c
LOCUS       BE666630                 183 bp    mRNA    linear   EST 25-APR-2001
DEFINITION  150209 MARC 4BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION   BE666630
VERSION     BE666630.1  GI:10027221
KEYWORDS    EST.
SOURCE      cow.
  ORGANISM  Bos taurus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
            Bovidae; Bovinae; Bos.
REFERENCE   1  (bases 1 to 183)
  AUTHORS   Smith,T.P.L., Grosse,W.M., Freking,B.A., Roberts,A.J., Stone,R.T.,
            Casas,E., Wray,J.E., White,J., Cho,J., Fahrenkrug,S.C., Bennett
            ,G.L., Heaton,M.P., Laegreid,W.W., Rohrer,G.A., Chitko-McKown,C.G.,
            Pertea,G., Holt,I., Karamycheva,S., Liang,F., Quackenbush,J. and
            Keele,J.W.
  TITLE     Sequence evaluation of four pooled-tissue normalized bovine cDNA
            libraries and construction of a gene index for cattle
  JOURNAL   Genome Res. 11 (4), 626-630 (2001)
  MEDLINE   21180013
COMMENT     Contact: Smith TPL
            USDA, ARS, US Meat Animal Research Center
            PO Box 166, Clay Center, NE 68933-0166, USA
            Tel: 402 762 4366
            Fax: 402 762 4390
            Email: smith@email.marc.usda.gov
            Single pass sequencing. Bases called and alt_trimmed with phred
            v0.980904.e. Vector identified by cross_match with the -minscore 18
            and -minmatch 12 options.
            PCR PRimers
            FORWARD: AGGAAACAGCTATGACCAT
            BACKWARD: GTTTTCCCAGTCACGACG
            Plate: 62  row: M  column: 15
            Seq primer: ATTTAGGTGACACTATAG.
FEATURES              Location/Qualifiers
     source           1. .183
                      /organism="Bos taurus"
                      /db_xref="taxon:9913"
                      /clone_lib="MARC 4BOV"
                      /tissue_type="pooled"
                      /lab_host="DH10B"
                      /note="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
                      Library made from pooled tissue from day 20 and day 40
                      embryos."
BASE COUNT       49 a     44 c     57 g     33 t
ORIGIN
```

```
  Query Match             100.0%;  Score 12;  DB 10;  Length 183;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    141 GGGGACTTTCCC 130


RESULT   7
BE667317/c
LOCUS       BE667317                183 bp    mRNA    linear   EST 25-APR-2001
DEFINITION  151609 MARC 4BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION   BE667317
VERSION     BE667317.1  GI:10027908
KEYWORDS    EST.
SOURCE      cow.
  ORGANISM  Bos taurus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
            Bovidae; Bovinae; Bos.
REFERENCE   1  (bases 1 to 183)
  AUTHORS   Smith,T.P.L., Grosse,W.M., Freking,B.A., Roberts,A.J., Stone,R.T.,
            Casas,E., Wray,J.E., White,J., Cho,J., Fahrenkrug,S.C., Bennett
            ,G.L., Heaton,M.P., Laegreid,W.W., Rohrer,G.A., Chitko-McKown,C.G.,
            Pertea,G., Holt,I., Karamycheva,S., Liang,F., Quackenbush,J. and
            Keele,J.W.
  TITLE     Sequence evaluation of four pooled-tissue normalized bovine cDNA
            libraries and construction of a gene index for cattle
  JOURNAL   Genome Res. 11 (4), 626-630 (2001)
  MEDLINE   21180013
COMMENT     Contact: Smith TPL
            USDA, ARS, US Meat Animal Research Center
            PO Box 166, Clay Center, NE 68933-0166, USA
            Tel: 402 762 4366
            Fax: 402 762 4390
            Email: smith@email.marc.usda.gov
            Single pass sequencing. Bases called and alt_trimmed with phred
            v0.980904.e. Vector identified by cross_match with the -minscore 18
            and -minmatch 12 options.
            PCR PRimers
            FORWARD: AGGAAACAGCTATGACCAT
            BACKWARD: GTTTTCCCAGTCACGACG
            Plate: 63  row: M  column: 15
            Seq primer: ATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .183
                     /organism="Bos taurus"
                     /db_xref="taxon:9913"
                     /clone_lib="MARC 4BOV"
                     /tissue_type="pooled"
                     /lab_host="DH10B"
                     /note="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
                     Library made from pooled tissue from day 20 and day 40
                     embryos."
BASE COUNT       49 a     44 c     57 g     33 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 10;  Length 183;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    141 GGGGACTTTCCC 130


RESULT   8
BH218996
LOCUS       BH218996                186 bp    DNA     linear   GSS 08-NOV-2001
DEFINITION  1006083F11.x1 1006 - RescueMu Grid G Zea mays genomic, DNA
            sequence.
ACCESSION   BH218996
VERSION     BH218996.1  GI:16812479
KEYWORDS    GSS.
SOURCE      Zea mays.
  ORGANISM  Zea mays
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACC
            clade; Panicoideae; Andropogoneae; Zea.
REFERENCE   1  (bases 1 to 186)
  AUTHORS   Walbot,V.
  TITLE     Maize genomic sequences found using engineered RescueMu transposon
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Walbot V
            Department of Biological Sciences
            Stanford University
            855 California Ave, Palo Alto, CA 94304, USA
            Tel: 650 723 2227
            Fax: 650 725 8221
            Email: walbot@stanford.edu
            Very probable ligation site found so sequence was trimmed.
            Post-ligation sequence submitted separately.
            Plate: 1006083  row: 33
            Class: transposon-tagged.
FEATURES             Location/Qualifiers
     source          1. .186
                     /organism="Zea mays"
                     /cultivar="mixed background W23/A188/B73"
                     /db_xref="taxon:4577"
                     /clone_lib="1006 - RescueMu Grid G"
                     /tissue_type="leaf"
                     /dev_stage="adult"
                     /lab_host="DH10B"
                     /note="Organ: leaf; Vector: RescueMu (engineered from
                     pBlueScript backbone); Site_1: BamHI; Site_2: BglII;
                     RescueMu is a 4.9 kb, modified maize Mu transposon
                     designed to allow plasmid rescue from total genomic DNA.
                     Mu elements insert preferentially into transcription
                     units. For more information on RescueMu, go to the web
                     site 'www.zmdb.iastate.edu' and follow the links for
                     'RescueMu.' Grid G was grown at Stanford in 2000. DNA was
                     extracted from leaf punches, double digested using BamHI
                     and BglII, and ligated to form circular plasmids. DH10B
                     cells were transformed and then screened on LB plates with
                     ampicillin."
BASE COUNT       39 a     68 c     40 g     39 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 12;  Length 186;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    104 GGGGACTTTCCC 115


RESULT   9
AA917080
LOCUS       AA917080                187 bp    mRNA    linear   EST 26-AUG-1998
DEFINITION  ol47g07.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone
            IMAGE:1526652 3' similar to SW:LAF4_HUMAN P51826 LAF-4 PROTEIN ;,
            mRNA sequence.
ACCESSION   AA917080
VERSION     AA917080.1  GI:3056472
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 187)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
```

```
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 1563   Std Error: 0.00
            Seq primer: -40m13 fwd. ET from Amersham
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .187
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:1526652"
                     /clone_lib="Soares_NFL_T_GBC_S1"
                     /lab_host="DH10B"
                     /note="Organ: pooled; Vector: pT7T3D-Pac (Pharmacia) with
                     a modified polylinker; Site_1: Not I; Site_2: Eco RI;
                     Equal amounts of plasmid DNA from three normalized
                     libraries (fetal lung NbHL19W, testis NHT, and B-cell
                     NCI_CGAP_GCB1) were mixed, and ss circles were made in
                     vitro. Following HAP purification, this DNA was used as
                     tracer in a subtractive hybridization reaction. The driver
                     was PCR-amplified cDNAs from pools of 5,000 clones made
                     from the same 3 libraries. The pools consisted of
                     I.M.A.G.E. clones 297480-302087, 682632-687239,
                     726408-728711, and 729096-731399. Subtraction by Bento
                     Soares and M. Fatima Bonaldo. "
BASE COUNT       41 a     46 c     47 g     52 t      1 others
ORIGIN
```

```
  Query Match             100.0%;  Score 12;  DB 9;  Length 187;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     83 GGGGACTTTCCC 94
```

```
RESULT  10
AW703817/c
LOCUS       AW703817                 190 bp    mRNA    linear   EST 03-DEC-2001
DEFINITION  sk13b08.y1 Gm-c1023 Glycine max cDNA clone GENOME SYSTEMS CLONE ID:
            Gm-c1023-3952 5', mRNA sequence.
ACCESSION   AW703817
VERSION     AW703817.1  GI:7588012
KEYWORDS    EST.
SOURCE      soybean.
  ORGANISM  Glycine max
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Rosidae; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
            Glycine.
REFERENCE   1  (bases 1 to 190)
  AUTHORS   Shoemaker,R., Keim,P., Vodkin,L., Erpelding,J., Coryell,V., Khanna
            ,A., Bolla,B., Marra,M., Hillier,L., Kucaba,T., Martin,J., Beck,C.,
            Wylie,T., Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers
            ,Y., Person,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk
            ,R., Ritter,E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann
            ,R., Waterston,R. and Wilson,R.
  TITLE     Public Soybean EST Project
  JOURNAL   Unpublished (1999)
COMMENT     Contact: Shoemaker R/Public Soybean EST Project
            Public Soybean EST Project
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            This clone is available through: ResGen, Invitrogen Corp. 2130
            South Memorial Parkway Huntsville, AL 35801 For further information
            call: (800)-533-4363 or contact via email: ccu@resgen.com
            High quality sequence stop: 180.
FEATURES             Location/Qualifiers
     source          1. .190
                     /organism="Glycine max"
                     /db_xref="taxon:3847"
                     /clone="GENOME SYSTEMS CLONE ID: Gm-c1023-3952"
                     /clone_lib="Gm-c1023"
                     /tissue_type="seed coats of greenhouse grown plants"
                     /lab_host="DH10B"
                     /note="Vector: pSPORT1; Site_1: SalI; Site_2: NotI; This
                     cDNA library was constructed from mRNA isolated from seed
                     coats (100-200mgs) of greenhouse grown plants.  The
                     library was prepared using the Life Technologies
                     pSuperScript cDNA library construction kit.  Complimentary
                     DNA was synthesized from mRNA using a poly (dT) sequence
                     with a Not I restrictions site.  Sal I linkers adapers
                     were ligated to the blunt-ended cDNA fragments followed by
                     Not I digestion.  The cDNA fragments were directionally
                     cloned into the Not I-Sal I restriction site of the
                     pSPORT1 vector.  The ligated cDNA fragments were
                     transformed into E.coli Electromax DH10B host cells. This
                     library was constructed by Dr. Lila Vodkin and Dr. Anu
                     Khanna."
BASE COUNT       58 a     35 c     51 g     46 t
ORIGIN
```

```
  Query Match             100.0%;  Score 12;  DB 9;  Length 190;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    156 GGGGACTTTCCC 145
```

```
RESULT  11
BE083238/c
LOCUS       BE083238                 191 bp    mRNA    linear   EST 12-JUN-2000
DEFINITION  RC3-BT0643-290200-011-d08 BT0643 Homo sapiens cDNA, mRNA sequence.
ACCESSION   BE083238
VERSION     BE083238.1  GI:8473557
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 191)
  AUTHORS   Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
            Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
            Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
            Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
            ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
            Simpson,A.J.
  TITLE     Shotgun sequencing of the human transcriptome with ORF expressed
            sequence tags
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
  MEDLINE   20202663
COMMENT     Contact: Simpson A.J.G.
            Laboratory of Cancer Genetics
            Ludwig Institute for Cancer Research
            Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
            Brazil
            Tel: +55-11-2704922
            Fax: +55-11-2707001
            Email: asimpson@ludwig.org.br
            This sequence was derived from the FAPESP/LICR Human Cancer Genome
            Project. This entry can be seen in the following URL
            (http://www.ludwig.org.br/scripts/gethtml2.pl?t1=&t2=RC3-BT0643-290
            200-011-d08&t3=2000-02-29&t4=1)
```

```
           Seq primer: puc 18 forward
           High quality sequence start: 25
           High quality sequence stop: 191.
FEATURES             Location/Qualifiers
     source          1. .191
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone_lib="BT0643"
                     /dev_stage="Adult"
                     /note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2:
                     SmaI; A mini-library was made by cloning products derived
                     from  ORESTES PCR (U.S. Letters Patent application No. 196
                     ,716 -  Ludwig Institute for Cancer Research) profiles
                     into  the pUC 18 vector. Reverse transcription of tissue
                     mRNA and cDNA amplification were performed under low
                     stringency conditions."
BASE COUNT       32 a     64 c     56 g     39 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 9;  Length 191;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     38 GGGGACTTTCCC 27


RESULT  12
AA613566/c
LOCUS       AA613566                 191 bp    mRNA    linear   EST 31-OCT-1997
DEFINITION  nq22f06.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1144643 3',
            mRNA sequence.
ACCESSION   AA613566
VERSION     AA613566.1  GI:2464604
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 191)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Ilan Kirsch, M.D., Michael R. Emmert-Buck, M.D.
            , Ph.D.
            cDNA Library Preparation: M. Bento Soares, Ph.D.
            cDNA Library Arrayed by: Greg Lennon, Ph.D.
            DNA Sequencing by: Washington University Genome Sequencing Center
            Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html
            Insert Length: 789   Std Error: 0.00
            Seq primer: -40m13 fwd. ET from Amersham
            High quality sequence stop: 177.
FEATURES             Location/Qualifiers
     source          1. .191
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:1144643"
                     /clone_lib="NCI_CGAP_Co10"
                     /tissue_type="colon tumor RER+"
                     /lab_host="DH10B"
                     /note="Organ: colon; Vector: pT7T3D-Pac (Pharmacia) with a
                     modified polylinker; 1st strand cDNA was prepared from
                     RER+ colon tumor, and was then primed with a Not I -
                     oligo(dT) primer. Double-stranded cDNA was ligated to Eco
                     RI adaptors (Pharmacia), digested with Not I and cloned
                     into the Not I and Eco RI sites of the modified pT7T3
                     vector.  Library is normalized. Library was constructed by
                     Bento Soares and M. Fatima Bonaldo (N-Soares4). "
BASE COUNT       60 a     46 c     54 g     31 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 9;  Length 191;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    162 GGGGACTTTCCC 151


RESULT  13
AW873686
LOCUS       AW873686                 192 bp    mRNA    linear   EST 22-MAY-2000
DEFINITION  hq28e02.x1 NCI_CGAP_Adr1 Homo sapiens cDNA clone IMAGE:3120698 3',
            mRNA sequence.
ACCESSION   AW873686
VERSION     AW873686.1  GI:8007739
KEYWORDS    EST.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 192)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Chris Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
            cDNA Library Preparation: Life Technologies, Inc.
            cDNA Library Arrayed by: The I.M.A.G.E. Consortium/LLNL
            DNA Sequencing by: Washington University Genome Sequencing Center
            Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL, send email to:
            info@image.llnl.gov
            Seq primer: -40UP from Gibco
            High quality sequence stop: 189.
FEATURES             Location/Qualifiers
     source          1. .192
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:3120698"
                     /clone_lib="NCI_CGAP_Adr1"
                     /tissue_type="neuroblastoma"
                     /lab_host="DH10B (phage-resistant)"
                     /note="Organ: adrenal gland; Vector: pCMV-SPORT6; Site_1:
                     NotI; Site_2: SalI; Cloned unidirectionally.  Primer:
                     Oligo dT.  Average insert size 1.2 kb.   Library
                     constructed by Life Technologies.  "
BASE COUNT       48 a     43 c     47 g     53 t      1 others
ORIGIN


  Query Match             100.0%;  Score 12;  DB 9;  Length 192;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    148 GGGGACTTTCCC 159


RESULT  14
AV357824
LOCUS       AV357824                 198 bp    mRNA    linear   EST 13-NOV-1999
DEFINITION  AV357824 RIKEN full-length enriched, in vitro fertilized eggs Mus
```

musculus cDNA clone 7420409H19 3', mRNA sequence.
ACCESSION AV357824
VERSION AV357824.1 GI:6404826
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 198)
AUTHORS Konno,H., Aizawa,K., Akahira,S., Akiyama,J., Carninci,P., Endo,T., Fukuda,S., Fukunishi,Y., Hara,A., Hayatsu,N., Hirozane,T., Hori,F., Ishii,Y., Ishikawa,T., Itoh,M., Izawa,M., Kadota,K., Kagawa,I., Kai,C., Kawai,J., Kikuchi,N., Kojima,Y., Koya,S., Kusakabe,M., Matsuyama,T., Miki,R., Mizuno,Y., Nakamura,M., Oda,H., Okazaki,Y., Owa,C., Ozawa,Y., Saito,H., Sano,M., Sato,K., Shibata,K., Shibata,Y., Shigemoto,Y., Shiraki,T., Sogabe,Y., Sugahara,Y., Suzuki,H., Suzuki,H., Takahashi,F., Tateno,M., Tominaga,N., Tsunoda,Y., Watahiki,A., Watanabe,S., Yamamura,T., Yasunishi,A., Yokota,T., Yoshiki,A., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.
TITLE RIKEN Mouse ESTs (Konno,H., et al. 1999)
JOURNAL Unpublished (1999)
COMMENT Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@gsc.riken.go.jp,
URL:http://genome.gsc.riken.go.jp/
Sasaki,N., Izawa,M., Watahiki,M., Ozawa,K., Tanaka,T., Yoneda,Y., Matsuura,S., Carninci,P., Muramatsu,M., Okazaki,Y. and Hayashizaki,Y.
Transcriptional sequencing: A method for DNA sequencing using RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 95 (7), 3455-3460 (1998)
Itoh,M., Kitsunai,T., Akiyama,J., Shibata,K., Izawa,M., Kawai,J., Tomaru,Y., Carninci,P., Shibata,Y., Ozawa,Y., Muramatsu,M., Okazaki,Y. and Hayashizaki,Y.
Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)
Carninci,P. and Hayashizaki,Y.
High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)
Please visit our web site (http://genome.rtc.riken.go.jp) for further details.
FEATURES Location/Qualifiers
source 1. .198
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="7420409H19"
/clone_lib="RIKEN full-length enriched, in vitro fertilized eggs"
/sex="female"
/tissue_type="in vitro fertilized eggs"
/dev_stage="egg"
/lab_host="DH10B"
/note="Site_1: SalI; Site_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGAGAGAGAAGGATCCAAGAGCTCTTTTTTTTTTTTTTTTVN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGAGATTCTCGAGTTAATTAAATTAATCCCCCCCCCCCCC 3']. cDNA was cloned into the XhoI and BamHI sites. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLC I. Cloning sites, 5' end: SalI; 3' end: BamHI"

BASE COUNT 53 a 42 c 55 g 48 t
ORIGIN

Query Match 100.0%; Score 12; DB 9; Length 198;
Best Local Similarity 100.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 92 GGGGACTTTCCC 103

RESULT 15
AI382447/c
LOCUS AI382447 201 bp mRNA linear EST 18-MAR-1999
DEFINITION ta72e07.x1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:2049636 3', mRNA sequence.
ACCESSION AI382447
VERSION AI382447.1 GI:4195228
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 201)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Insert Length: 473 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 190.
FEATURES Location/Qualifiers
source 1. .201
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2049636"
/clone_lib="Soares_total_fetus_Nb2HF8_9w"
/dev_stage="8-9 weeks"
/lab_host="DH10B"
/note="Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was prepared from mRNA obtained from pooled 8-9 week (total) fetus material with a Not I - oligo(dT) primer [5' TGTTACCAATCTGAAGTGGGAGCGGCCGCTTAATTTTTTTTTTTTTTTT 3']. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization, and was constructed by Bento Soares and M. Fatima Bonaldo. "
BASE COUNT 62 a 39 c 30 g 70 t
ORIGIN

Query Match 100.0%; Score 12; DB 9; Length 201;
Best Local Similarity 100.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 71 GGGGACTTTCCC 60

Search completed: September 22, 2002, 12:49:38
Job time: 5023 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 12:21:04 ; Search time 2898.72 Seconds
(without alignments)
89.563 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggactttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 21979536 seqs, 10817449327 residues

Total number of hits satisfying chosen parameters: 43959072

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_NA_Main:*
1: /cgn2_6/ptodata/1/pna/PCTUS_COMB.seq:*
2: /cgn2_6/ptodata/1/pna/US06_COMB.seq:*
3: /cgn2_6/ptodata/1/pna/US07_COMB.seq:*
4: /cgn2_6/ptodata/1/pna/US080_COMB.seq:*
5: /cgn2_6/ptodata/1/pna/US081_COMB.seq:*
6: /cgn2_6/ptodata/1/pna/US082_COMB.seq:*
7: /cgn2_6/ptodata/1/pna/US083_COMB.seq:*
8: /cgn2_6/ptodata/1/pna/US084_COMB.seq:*
9: /cgn2_6/ptodata/1/pna/US085_COMB.seq:*
10: /cgn2_6/ptodata/1/pna/US086_COMB.seq:*
11: /cgn2_6/ptodata/1/pna/US087_COMB.seq:*
12: /cgn2_6/ptodata/1/pna/US088_COMB.seq:*
13: /cgn2_6/ptodata/1/pna/US089_COMB.seq:*
14: /cgn2_6/ptodata/1/pna/US090_COMB.seq:*
15: /cgn2_6/ptodata/1/pna/US091_COMB.seq:*
16: /cgn2_6/ptodata/1/pna/US092_COMB.seq:*
17: /cgn2_6/ptodata/1/pna/US093_COMB.seq:*
18: /cgn2_6/ptodata/1/pna/US094_COMB.seq:*
19: /cgn2_6/ptodata/1/pna/US095A_COMB.seq:*
20: /cgn2_6/ptodata/1/pna/US095B_COMB.seq:*
21: /cgn2_6/ptodata/1/pna/US095C_COMB.seq:*
22: /cgn2_6/ptodata/1/pna/US095D_COMB.seq:*
23: /cgn2_6/ptodata/1/pna/US096A_COMB.seq:*
24: /cgn2_6/ptodata/1/pna/US096B_COMB.seq:*
25: /cgn2_6/ptodata/1/pna/US096C_COMB.seq:*
26: /cgn2_6/ptodata/1/pna/US096D_COMB.seq:*
27: /cgn2_6/ptodata/1/pna/US096E_COMB.seq:*
28: /cgn2_6/ptodata/1/pna/US097A_COMB.seq:*
29: /cgn2_6/ptodata/1/pna/US097B_COMB.seq:*
30: /cgn2_6/ptodata/1/pna/US097C_COMB.seq:*
31: /cgn2_6/ptodata/1/pna/US098A_COMB.seq:*
32: /cgn2_6/ptodata/1/pna/US098B_COMB.seq:*
33: /cgn2_6/ptodata/1/pna/US098C_COMB.seq:*
34: /cgn2_6/ptodata/1/pna/US099A_COMB.seq:*
35: /cgn2_6/ptodata/1/pna/US099B_COMB.seq:*
36: /cgn2_6/ptodata/1/pna/US099C_COMB.seq:*
37: /cgn2_6/ptodata/1/pna/US100_COMB.seq:*
38: /cgn2_6/ptodata/1/pna/US101_COMB.seq:*
39: /cgn2_6/ptodata/1/pna/US6000_COMB.seq:*
40: /cgn2_6/ptodata/1/pna/US6001_COMB.seq:*
41: /cgn2_6/ptodata/1/pna/US6002_COMB.seq:*
42: /cgn2_6/ptodata/1/pna/US6003_COMB.seq:*
43: /cgn2_6/ptodata/1/pna/US6004_COMB.seq:*
44: /cgn2_6/ptodata/1/pna/US6005_COMB.seq:*
45: /cgn2_6/ptodata/1/pna/US6006_COMB.seq:*
46: /cgn2_6/ptodata/1/pna/US6007_COMB.seq:*
47: /cgn2_6/ptodata/1/pna/US6008_COMB.seq:*
48: /cgn2_6/ptodata/1/pna/US6009_COMB.seq:*
49: /cgn2_6/ptodata/1/pna/US6010_COMB.seq:*
50: /cgn2_6/ptodata/1/pna/US6011_COMB.seq:*
51: /cgn2_6/ptodata/1/pna/US6012_COMB.seq:*
52: /cgn2_6/ptodata/1/pna/US6013_COMB.seq:*
53: /cgn2_6/ptodata/1/pna/US6014_COMB.seq:*
54: /cgn2_6/ptodata/1/pna/US6015_COMB.seq:*
55: /cgn2_6/ptodata/1/pna/US6016_COMB.seq:*
56: /cgn2_6/ptodata/1/pna/US6017_COMB.seq:*
57: /cgn2_6/ptodata/1/pna/US6018_COMB.seq:*
58: /cgn2_6/ptodata/1/pna/US6019_COMB.seq:*
59: /cgn2_6/ptodata/1/pna/US6020_COMB.seq:*
60: /cgn2_6/ptodata/1/pna/US6021_COMB.seq:*
61: /cgn2_6/ptodata/1/pna/US6022_COMB.seq:*
62: /cgn2_6/ptodata/1/pna/US6023_COMB.seq:*
63: /cgn2_6/ptodata/1/pna/US6024_COMB.seq:*
64: /cgn2_6/ptodata/1/pna/US6025_COMB.seq:*
65: /cgn2_6/ptodata/1/pna/US6026_COMB.seq:*
66: /cgn2_6/ptodata/1/pna/US6027_COMB.seq:*
67: /cgn2_6/ptodata/1/pna/US6028_COMB.seq:*
68: /cgn2_6/ptodata/1/pna/US6029_COMB.seq:*
69: /cgn2_6/ptodata/1/pna/US6030_COMB.seq:*
70: /cgn2_6/ptodata/1/pna/US6031_COMB.seq:*
71: /cgn2_6/ptodata/1/pna/US6032_COMB.seq:*
72: /cgn2_6/ptodata/1/pna/US6033_COMB.seq:*
73: /cgn2_6/ptodata/1/pna/US6034_COMB.seq:*
74: /cgn2_6/ptodata/1/pna/US6035_COMB.seq:*
75: /cgn2_6/ptodata/1/pna/US6036_COMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	12	100.0	12	1	PCT-US00-00770-16	Sequence 16, Appl
2	12	100.0	12	1	PCT-US00-00807-23	Sequence 23, Appl
3	12	100.0	12	1	PCT-US00-00903-8	Sequence 8, Appli
4	12	100.0	12	1	PCT-US00-01239-30	Sequence 30, Appl
5	12	100.0	12	1	PCT-US00-03062-8	Sequence 8, Appli
6	12	100.0	12	1	PCT-US00-03062-8	Sequence 8, Appli
7	12	100.0	12	1	PCT-US00-04572-24	Sequence 24, Appl
8	12	100.0	12	1	PCT-US00-05881-844	Sequence 844, App
9	12	100.0	12	1	PCT-US00-05882-1692	Sequence 1692, Ap
10	12	100.0	12	1	PCT-US00-05883-1554	Sequence 1554, Ap
11	12	100.0	12	1	PCT-US00-05918-894	Sequence 894, App
12	12	100.0	12	1	PCT-US00-05988-1888	Sequence 1888, Ap
13	12	100.0	12	1	PCT-US00-05989-926	Sequence 926, App
14	12	100.0	12	1	PCT-US00-06012-8	Sequence 8, Appli
15	12	100.0	12	1	PCT-US00-06013-8	Sequence 8, Appli
16	12	100.0	12	1	PCT-US00-06014-8	Sequence 8, Appli
17	12	100.0	12	1	PCT-US00-06043-8	Sequence 8, Appli
18	12	100.0	12	1	PCT-US00-06049-8	Sequence 8, Appli
19	12	100.0	12	1	PCT-US00-06057-8	Sequence 8, Appli
20	12	100.0	12	1	PCT-US00-06059-8	Sequence 8, Appli
21	12	100.0	12	1	PCT-US00-06765-8	Sequence 8, Appli
22	12	100.0	12	1	PCT-US00-06765-8	Sequence 8, Appli
23	12	100.0	12	1	PCT-US00-06781-8	Sequence 8, Appli
24	12	100.0	12	1	PCT-US00-06782-8	Sequence 8, Appli
25	12	100.0	12	1	PCT-US00-06783-8	Sequence 8, Appli
26	12	100.0	12	1	PCT-US00-06791-8	Sequence 8, Appli
27	12	100.0	12	1	PCT-US00-06792-8	Sequence 8, Appli
28	12	100.0	12	1	PCT-US00-06792-8	Sequence 8, Appli
29	12	100.0	12	1	PCT-US00-06822-8	Sequence 8, Appli
30	12	100.0	12	1	PCT-US00-06823-8	Sequence 8, Appli
31	12	100.0	12	1	PCT-US00-06824-8	Sequence 8, Appli

32	12	100.0	12	1	PCT-US00-06828-8	Sequence 8, Appli
33	12	100.0	12	1	PCT-US00-06830-8	Sequence 8, Appli
34	12	100.0	12	1	PCT-US00-07440-8	Sequence 8, Appli
35	12	100.0	12	1	PCT-US00-07440A-8	Sequence 8, Appli
36	12	100.0	12	1	PCT-US00-07483-8	Sequence 8, Appli
37	12	100.0	12	1	PCT-US00-07505-8	Sequence 8, Appli
38	12	100.0	12	1	PCT-US00-07506-8	Sequence 8, Appli
39	12	100.0	12	1	PCT-US00-07507-8	Sequence 8, Appli
40	12	100.0	12	1	PCT-US00-07526-8	Sequence 8, Appli
41	12	100.0	12	1	PCT-US00-07527-8	Sequence 8, Appli
42	12	100.0	12	1	PCT-US00-07534-8	Sequence 8, Appli
43	12	100.0	12	1	PCT-US00-07534-8	Sequence 8, Appli
44	12	100.0	12	1	PCT-US00-07535-8	Sequence 8, Appli
45	12	100.0	12	1	PCT-US00-07578-8	Sequence 8, Appli

ALIGNMENTS

```
RESULT   1
PCT-US00-00770-16
; Sequence 16, Application PC/TUS0000770
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Bone Marrow-Specific Protein
;  FILE REFERENCE: PF495.PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/00770
;  CURRENT FILING DATE: 2000-01-13
;  EARLIER APPLICATION NUMBER: 60/116,236
;  EARLIER FILING DATE: 1999-01-15
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-00770-16


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   2
PCT-US00-00807-23
; Sequence 23, Application PC/TUS0000807
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Interleukin-20
;  FILE REFERENCE: PF399PCT2
;  CURRENT APPLICATION NUMBER: PCT/US00/00807
;  CURRENT FILING DATE: 2000-01-14
;  EARLIER APPLICATION NUMBER: 09/231,788
;  EARLIER FILING DATE: 1999-01-15
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 23
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-00807-23


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   3
PCT-US00-00903-8
; Sequence 8, Application PC/TUS0000903
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: 33 Human Secreted Proteins
;  FILE REFERENCE: PZ036.PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/00903
;  CURRENT FILING DATE: 2000-01-18
;  EARLIER APPLICATION NUMBER: 60/116,330
;  EARLIER FILING DATE: 1999-01-19
;  NUMBER OF SEQ ID NOS: 144
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-00903-8


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   4
PCT-US00-01239-30
; Sequence 30, Application PC/TUS0001239
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Keratinocyte Derived Interferon
;  FILE REFERENCE: PF482P1
;  CURRENT APPLICATION NUMBER: PCT/US00/01239
;  CURRENT FILING DATE: 2000-01-20
;  EARLIER APPLICATION NUMBER: 60/093,643
;  EARLIER FILING DATE: 1998-07-21
;  EARLIER APPLICATION NUMBER: PCT/US99/16424
;  EARLIER FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 54
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-01239-30


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   5
PCT-US00-03062-8
; Sequence 8, Application PC/TUS0003062A
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: 33 Human secreted proteins
;  FILE REFERENCE: PZ037.PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/03062A
;  CURRENT FILING DATE: 2000-02-08
```

```
;  EARLIER APPLICATION NUMBER: 60/119,468
;  EARLIER FILING DATE: 1999-02-10
;  NUMBER OF SEQ ID NOS: 170
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-03062-8


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   6
PCT-US00-03062-8
; Sequence 8, Application PC/TUS0003062B
; GENERAL INFORMATION:
;  APPLICANT:   Human Genome Sciences, Inc.
;  TITLE OF INVENTION:  33 Human secreted proteins
;  FILE REFERENCE:  PZ037.PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/03062B
;  CURRENT FILING DATE:  2000-02-08
;  PRIOR APPLICATION NUMBER:  60/119,468
;  PRIOR FILING DATE:  1999-02-10
;  NUMBER OF SEQ ID NOS:  170
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-03062-8


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   7
PCT-US00-04572-24
; Sequence 24, Application PC/TUS0004572
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Tumor Necrosis Factor Receptor-Like Proteins
;  TITLE OF INVENTION: TR11, TR11SV1, and TR11SV2
;  FILE REFERENCE: PF396.PCT2
;  CURRENT APPLICATION NUMBER: PCT/US00/04572
;  CURRENT FILING DATE: 2000-02-23
;  EARLIER APPLICATION NUMBER: 60/121,648
;  EARLIER FILING DATE: 1999-02-24
;  EARLIER APPLICATION NUMBER: 60/134,172
;  EARLIER FILING DATE: 1999-05-13
;  EARLIER APPLICATION NUMBER: 60/144,076
;  EARLIER FILING DATE: 1999-07-16
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 24
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-04572-24


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   8
PCT-US00-05881-844
; Sequence 844, Application PC/TUS0005881
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Breast and Ovarian Cancer Associated Gene Sequences and
;  FILE REFERENCE: PA103PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05881
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 846
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 844
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05881-844


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   9
PCT-US00-05882-1692
; Sequence 1692, Application PC/TUS0005882
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Cancer Associated Gene Sequences and Polypeptides
;  FILE REFERENCE: PA106PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05882
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 1694
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1692
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05882-1692


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  10
PCT-US00-05883-1554
; Sequence 1554, Application PC/TUS0005883
```

```
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Colon Cancer Associated Gene Sequences and Polypeptides
;  FILE REFERENCE: PA102PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05883
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 1556
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1554
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05883-1554


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  11
PCT-US00-05918-894
; Sequence 894, Application PC/TUS0005918
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Lung Cancer Associated Gene Sequences and Polypeptides
;  FILE REFERENCE: PA104PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05918
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 896
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 894
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05918-894


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  12
PCT-US00-05988-1888
; Sequence 1888, Application PC/TUS0005988
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Prostate Cancer Associated Gene Sequences and Polypeptides
;  FILE REFERENCE: PA101PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05988
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 1890
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1888
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05988-1888


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  13
PCT-US00-05989-926
; Sequence 926, Application PC/TUS0005989
; GENERAL INFORMATION:
;  APPLICANT: Craig Rosen,
;  APPLICANT: Steve Ruben
;  TITLE OF INVENTION: Human Pancreas and Pancreatic Cancer Associated Gene Sequences
;  TITLE OF INVENTION: Polypeptides
;  FILE REFERENCE: PA105PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/05989
;  CURRENT FILING DATE: 2000-03-08
;  EARLIER APPLICATION NUMBER: 60/124,270
;  EARLIER FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 928
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 926
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-05989-926


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  14
PCT-US00-06012-8
; Sequence 8, Application PC/TUS0006012
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 50 Human Secreted Proteins
;  FILE REFERENCE: PS502PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/06012
;  CURRENT FILING DATE: 2000-03-09
;  EARLIER APPLICATION NUMBER: 60/124,093
;  EARLIER FILING DATE: 1999-03-12
;  EARLIER APPLICATION NUMBER: 60/166,989
;  EARLIER FILING DATE: 1999-11-23
;  NUMBER OF SEQ ID NOS: 142
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-06012-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
```

```
Db      1 ggggactttccc 12


RESULT  15
PCT-US00-06013-8
; Sequence 8, Application PC/TUS0006013
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: 50 Human Secreted Proteins
;  FILE REFERENCE: PS508PCT
;  CURRENT APPLICATION NUMBER: PCT/US00/06013
;  CURRENT FILING DATE: 2000-03-09
;  EARLIER APPLICATION NUMBER: 60/125,360
;  EARLIER FILING DATE: 1999-03-19
;  EARLIER APPLICATION NUMBER: 60/138,626
;  EARLIER FILING DATE: 1999-06-11
;  EARLIER APPLICATION NUMBER: 60/168,662
;  EARLIER FILING DATE: 1999-12-03
;  NUMBER OF SEQ ID NOS: 170
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US00-06013-8


  Query Match            100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


Search completed: September 22, 2002, 14:14:46
Job time: 6822 sec
```

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 12:49:45 ; Search time 325.71 Seconds
(without alignments)
118.209 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggactttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2138461 seqs, 1604250230 residues

Total number of hits satisfying chosen parameters: 4276922

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_NA_New:*
1: /cgn2_6/ptodata/2/pna/PCT_NEW_COMB.seq:*
2: /cgn2_6/ptodata/2/pna/US06_NEW_COMB.seq:*
3: /cgn2_6/ptodata/2/pna/US07_NEW_COMB.seq:*
4: /cgn2_6/ptodata/2/pna/US08_NEW_COMB.seq:*
5: /cgn2_6/ptodata/2/pna/US09_NEW_COMB.seq:*
6: /cgn2_6/ptodata/2/pna/US10_NEW_COMB.seq:*
7: /cgn2_6/ptodata/2/pna/US10_NEW_COMB.seq2:*
8: /cgn2_6/ptodata/2/pna/US60_NEW_COMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	12	100.0	12	1	PCT-US02-01109-8	Sequence 8, Appli
2	12	100.0	12	1	PCT-US02-06990-8	Sequence 8, Appli
3	12	100.0	12	1	PCT-US02-09239-8	Sequence 8, Appli
4	12	100.0	12	1	PCT-US02-09135-8	Sequence 8, Appli
5	12	100.0	12	1	PCT-US02-09105-8	Sequence 8, Appli
6	12	100.0	12	1	PCT-US02-09188-8	Sequence 8, Appli
7	12	100.0	12	1	PCT-US02-09257-8	Sequence 8, Appli
8	12	100.0	12	1	PCT-US02-09370-8	Sequence 8, Appli
9	12	100.0	12	1	PCT-US02-09785-8	Sequence 8, Appli
10	12	100.0	12	1	PCT-US02-09922-8	Sequence 8, Appli
11	12	100.0	12	1	PCT-US02-17699-8	Sequence 8, Appli
12	12	100.0	12	1	PCT-US02-23214-30	Sequence 30, Appl
13	12	100.0	12	1	PCT-US02-25107-8	Sequence 8, Appli
14	12	100.0	12	1	PCT-US02-21857-14	Sequence 14, Appl
15	12	100.0	12	5	US-09-852-659A-8	Sequence 8, Appli
16	12	100.0	12	5	US-09-572-406B-26	Sequence 26, Appl
17	12	100.0	12	5	US-09-813-153-8	Sequence 8, Appli
18	12	100.0	12	5	US-09-764-882A-8	Sequence 8, Appli
19	12	100.0	12	5	US-09-997-003-8	Sequence 8, Appli
20	12	100.0	12	6	US-10-195-730-8	Sequence 8, Appli
21	12	100.0	12	6	US-10-197-816-30	Sequence 30, Appl
22	12	100.0	12	6	US-10-153-064A-30	Sequence 30, Appl
23	12	100.0	12	6	US-10-200-537-8	Sequence 8, Appli
24	12	100.0	12	6	US-10-201-109-8	Sequence 8, Appli
25	12	100.0	12	6	US-10-153-064-30	Sequence 30, Appl
26	12	100.0	12	6	US-10-207-037-8	Sequence 8, Appli
27	12	100.0	12	6	US-10-201-255-8	Sequence 8, Appli
28	12	100.0	12	6	US-10-201-915-8	Sequence 8, Appli
29	12	100.0	12	6	US-10-205-303-8	Sequence 8, Appli
30	12	100.0	12	6	US-10-206-002-8	Sequence 8, Appli
31	12	100.0	12	6	US-10-206-008-8	Sequence 8, Appli
32	12	100.0	12	6	US-10-206-021-8	Sequence 8, Appli
33	12	100.0	12	6	US-10-206-272-8	Sequence 8, Appli
34	12	100.0	12	6	US-10-206-664-8	Sequence 8, Appli
35	12	100.0	12	6	US-10-211-725-8	Sequence 8, Appli
36	12	100.0	12	6	US-10-211-798-8	Sequence 8, Appli
37	12	100.0	12	6	US-10-211-818-8	Sequence 8, Appli
38	12	100.0	12	6	US-10-212-072-8	Sequence 8, Appli
39	12	100.0	12	6	US-10-207-175-8	Sequence 8, Appli
40	12	100.0	12	6	US-10-211-346-8	Sequence 8, Appli
41	12	100.0	12	6	US-10-211-364-8	Sequence 8, Appli
42	12	100.0	12	6	US-10-211-625-8	Sequence 8, Appli
43	12	100.0	12	6	US-10-212-054-8	Sequence 8, Appli
44	12	100.0	12	6	US-10-212-059-8	Sequence 8, Appli
45	12	100.0	12	6	US-10-212-083-8	Sequence 8, Appli

ALIGNMENTS

```
RESULT   1
PCT-US02-01109-8
; Sequence 8, Application PC/TUS0201109
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: 50 Human Secreted Proteins
;  FILE REFERENCE: PZ016PCT2
;  CURRENT APPLICATION NUMBER: PCT/US02/01109
;  CURRENT FILING DATE:  2002-01-17
;  PRIOR APPLICATION NUMBER: US 60/262,066
;  PRIOR FILING DATE: 2001-01-18
;  NUMBER OF SEQ ID NOS: 206
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-01109-8


  Query Match           100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   2
PCT-US02-06990-8
; Sequence 8, Application PC/TUS0206990
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PF534PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/06990
;  CURRENT FILING DATE:  2002-03-08
;  PRIOR APPLICATION NUMBER: 60/274,214
;  PRIOR FILING DATE: 2001-03-09
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-06990-8
```

```
  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   3
PCT-US02-09239-8
; Sequence 8, Application PC/TUS0209239
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS953PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09239
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 380
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09239-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   4
PCT-US02-09135-8
; Sequence 8, Application PC/TUS0209135
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS956PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09135
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 491
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09135-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   5
PCT-US02-09105-8
; Sequence 8, Application PC/TUS0209105
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS951PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09105
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 779
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09105-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   6
PCT-US02-09188-8
; Sequence 8, Application PC/TUS0209188
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS952PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09188
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 1732
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09188-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   7
PCT-US02-09257-8
; Sequence 8, Application PC/TUS0209257
; GENERAL INFORMATION:
```

```
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS957PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09257
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 994
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09257-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   8
PCT-US02-09370-8
; Sequence 8, Application PC/TUS0209370
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS954PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09370
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 1834
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09370-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   9
PCT-US02-09785-8
; Sequence 8, Application PC/TUS0209785
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS905PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09785
;  CURRENT FILING DATE:  2002-03-19
;  PRIOR APPLICATION NUMBER: US 60/331,287
;  PRIOR FILING DATE: 2001-11-13
;  PRIOR APPLICATION NUMBER: US 60/306,171
;  PRIOR FILING DATE: 2001-07-19
;  PRIOR APPLICATION NUMBER: US 60/277,340
;  PRIOR FILING DATE: 2001-03-21
;  NUMBER OF SEQ ID NOS: 1130
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09785-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  10
PCT-US02-09922-8
; Sequence 8, Application PC/TUS0209922
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Human Secreted Proteins
;  FILE REFERENCE: PS955PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/09922
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/278,650
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 09/950,082
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US 09/950,083
;  PRIOR FILING DATE: 2001-09-12
;  NUMBER OF SEQ ID NOS: 1117
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-09922-8


  Query Match             100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  11
PCT-US02-17699-8
; Sequence 8, Application PC/TUS0217699
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc., et al.
;  TITLE OF INVENTION: Secreted Proteins From Diabetes-Related Tissues
;  FILE REFERENCE: PS737PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/17699
;  CURRENT FILING DATE:  2002-06-05
;  NUMBER OF SEQ ID NOS: 118
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-17699-8
```

```
  Query Match           100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  12
PCT-US02-23214-30
; Sequence 30, Application PC/TUS0223214
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Keratinocyte Derived Interferon
;  FILE REFERENCE: PF482PCT3
;  CURRENT APPLICATION NUMBER: PCT/US02/23214
;  CURRENT FILING DATE:  2002-07-19
;  PRIOR APPLICATION NUMBER: 60/336,165
;  PRIOR FILING DATE: 2001-12-06
;  PRIOR APPLICATION NUMBER: 09/908,594
;  PRIOR FILING DATE: 2001-07-20
;  NUMBER OF SEQ ID NOS: 57
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-23214-30


  Query Match           100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  13
PCT-US02-25107-8
; Sequence 8, Application PC/TUS0225107
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: 13 Human Secreted Proteins
;  FILE REFERENCE: PS738PCT
;  CURRENT APPLICATION NUMBER: PCT/US02/25107
;  CURRENT FILING DATE:  2002-08-08
;  PRIOR APPLICATION NUMBER: US 60/311,085
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: US 60/325,209
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 72
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
PCT-US02-25107-8


  Query Match           100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  14
PCT-US02-21857-14
; Sequence 14, Application PC/TUS0221857
; GENERAL INFORMATION:
;  APPLICANT: Eli Lilly and Company
;  TITLE OF INVENTION: LP Mammalian Proteins: Related Reagents Field of the Invention
;  FILE REFERENCE: X-14499
;  CURRENT APPLICATION NUMBER: PCT/US02/21857
;  CURRENT FILING DATE:  2002-08-23
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
PCT-US02-21857-14


  Query Match           100.0%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  15
US-09-852-659A-8
; Sequence 8, Application US/09852659A
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 28 Human Secreted Proteins
;  FILE REFERENCE: PZ003P4
;  CURRENT APPLICATION NUMBER: US/09/852,659A
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: 60/265,583
;  PRIOR FILING DATE: 2001-02-02
;  PRIOR APPLICATION NUMBER: 09/152,060
;  PRIOR FILING DATE: 1998-09-11
;  PRIOR APPLICATION NUMBER: PCT/US98/04858
;  PRIOR FILING DATE: 1998-03-12
;  PRIOR APPLICATION NUMBER: 60/040,762
;  PRIOR FILING DATE: 1997-03-14
;  PRIOR APPLICATION NUMBER: 60/040,710
;  PRIOR FILING DATE: 1997-03-14
;  PRIOR APPLICATION NUMBER: 60/050,934
;  PRIOR FILING DATE: 1997-05-30
;  PRIOR APPLICATION NUMBER: 60/048,100
;  PRIOR FILING DATE: 1997-05-30
;  PRIOR APPLICATION NUMBER: 60/048,357
;  PRIOR FILING DATE: 1997-05-30
;  PRIOR APPLICATION NUMBER: 60/048,189
;  PRIOR FILING DATE: 1997-05-30
;  PRIOR APPLICATION NUMBER: 60/057,765
;  PRIOR FILING DATE: 1997-09-05
;  PRIOR APPLICATION NUMBER: 60/048,970
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/068,368
;  PRIOR FILING DATE: 1997-12-19
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-852-659A-8


  Query Match           100.0%;  Score 12;  DB 5;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12
```

Search completed: September 22, 2002, 14:20:34
Job time: 5449 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 12:15:14 ; Search time 213.26 Seconds
(without alignments)
96.610 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggactttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	12	100.0	12	19	AAV34151	Upstream primer fo
2	12	100.0	12	19	AAV59508	Upstream primer fo
3	12	100.0	12	19	AAV34283	Upstream primer fo
4	12	100.0	12	19	AAV69608	Upstream primer fo
5	12	100.0	12	20	AAZ32078	Nuclear factor KB
6	12	100.0	12	20	AAZ24808	Nuclear factor kap
7	12	100.0	12	20	AAZ09781	Nuclear factor kap
8	12	100.0	12	20	AAZ00407	Human NF-KappaB bi
9	12	100.0	12	20	AAZ00799	NF-kappaB DNA bind
10	12	100.0	12	20	AAZ06216	Nuclear factor kap
11	12	100.0	12	20	AAX97913	Nuclear factor kap
12	12	100.0	12	20	AAX79008	Upstream primer fo
13	12	100.0	12	20	AAX84930	Nuclear factor kap
14	12	100.0	12	20	AAX37366	Human NF-kappaB pr
15	12	100.0	12	20	AAX37448	NF-KappaB promoter
16	12	100.0	12	20	AAX27308	Nuclear factor kap
17	12	100.0	12	20	AAX30180	Nuclear factor kap
18	12	100.0	12	20	AAX22208	Upstream primer fo
19	12	100.0	12	20	AAX22108	Upstream primer fo
20	12	100.0	12	20	AAX30314	Nucleotide sequenc
21	12	100.0	12	20	AAX20409	Nuclear factor kap
22	12	100.0	12	20	AAX16175	Nuclear factor-kB
23	12	100.0	12	20	AAX04308	Nuclear factor kap
24	12	100.0	12	20	AAX00608	Nuclear factor kap
25	12	100.0	12	20	AAV84408	Upstream primer fo
26	12	100.0	12	21	AAD02084	Nuclear factor kap
27	12	100.0	12	21	AAD02236	Nuclear factor Kap
28	12	100.0	12	21	AAF22038	Nuclear factor Kap
29	12	100.0	12	21	AAF22313	Nuclear factor kap
30	12	100.0	12	21	AAF22370	Nuclear factor kap
31	12	100.0	12	21	AAC98770	Nuclear factor kap
32	12	100.0	12	21	AAC99238	Nuclear factor kap
33	12	100.0	12	21	AAC99815	Nuclear factor kap
34	12	100.0	12	21	AAF16512	Nuclear factor kap
35	12	100.0	12	21	AAF18431	Nuclear factor Kap
36	12	100.0	12	21	AAC66407	NF-kappaB promoter
37	12	100.0	12	21	AAC67628	Nuclear factor kap
38	12	100.0	12	21	AAC68078	Nuclear factor kap
39	12	100.0	12	21	AAC81707	NF-kappaB promoter
40	12	100.0	12	21	AAC93307	Nuclear factor kap
41	12	100.0	12	21	AAC93361	Nuclear factor kap
42	12	100.0	12	21	AAC93419	Nuclear factor kap
43	12	100.0	12	21	AAC93476	Nuclear factor kap
44	12	100.0	12	21	AAC95459	Nuclear factor kap
45	12	100.0	12	21	AAC95518	Nuclear factor kap

ALIGNMENTS

RESULT 1
AAV34151
ID AAV34151 standard; DNA; 12 BP.
XX
AC AAV34151;
XX
DT 02-FEB-1999 (first entry)
XX
DE Upstream primer for nuclear factor kappa-B gene promoter.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9839446-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US04492.
XX
PR 07-MAR-1997; 97US-0038621.
PR 07-MAR-1997; 97US-0040161.
PR 07-MAR-1997; 97US-0040162.
PR 07-MAR-1997; 97US-0040163.

PR 07-MAR-1997; 97US-0040333.
PR 07-MAR-1997; 97US-0040334.
PR 07-MAR-1997; 97US-0040336.
PR 07-MAR-1997; 97US-0040626.
PR 11-APR-1997; 97US-0043311.
PR 11-APR-1997; 97US-0043312.
PR 11-APR-1997; 97US-0043313.
PR 11-APR-1997; 97US-0043314.
PR 11-APR-1997; 97US-0043315.
PR 11-APR-1997; 97US-0043568.
PR 11-APR-1997; 97US-0043569.
PR 11-APR-1997; 97US-0043576.
PR 11-APR-1997; 97US-0043578.
PR 11-APR-1997; 97US-0043580.
PR 11-APR-1997; 97US-0043669.
PR 11-APR-1997; 97US-0043670.
PR 11-APR-1997; 97US-0043671.
PR 11-APR-1997; 97US-0043672.
PR 11-APR-1997; 97US-0043674.
PR 23-MAY-1997; 97US-0047492.
PR 23-MAY-1997; 97US-0047500.
PR 23-MAY-1997; 97US-0047501.
PR 23-MAY-1997; 97US-0047502.
PR 23-MAY-1997; 97US-0047503.
PR 23-MAY-1997; 97US-0047581.
PR 23-MAY-1997; 97US-0047582.
PR 23-MAY-1997; 97US-0047583.
PR 23-MAY-1997; 97US-0047584.
PR 23-MAY-1997; 97US-0047585.
PR 23-MAY-1997; 97US-0047586.
PR 23-MAY-1997; 97US-0047587.
PR 23-MAY-1997; 97US-0047588.
PR 23-MAY-1997; 97US-0047589.
PR 23-MAY-1997; 97US-0047590.
PR 23-MAY-1997; 97US-0047592.
PR 23-MAY-1997; 97US-0047593.
PR 23-MAY-1997; 97US-0047594.
PR 23-MAY-1997; 97US-0047595.
PR 23-MAY-1997; 97US-0047596.
PR 23-MAY-1997; 97US-0047597.
PR 23-MAY-1997; 97US-0047598.
PR 23-MAY-1997; 97US-0047599.
PR 23-MAY-1997; 97US-0047600.
PR 23-MAY-1997; 97US-0047601.
PR 23-MAY-1997; 97US-0047612.
PR 23-MAY-1997; 97US-0047613.
PR 23-MAY-1997; 97US-0047614.
PR 23-MAY-1997; 97US-0047615.
PR 23-MAY-1997; 97US-0047617.
PR 23-MAY-1997; 97US-0047618.
PR 23-MAY-1997; 97US-0047632.
PR 23-MAY-1997; 97US-0047633.
PR 06-JUN-1997; 97US-0048964.
PR 06-JUN-1997; 97US-0048974.
PR 22-AUG-1997; 97US-0056630.
PR 22-AUG-1997; 97US-0056631.
PR 22-AUG-1997; 97US-0056632.
PR 22-AUG-1997; 97US-0056636.
PR 22-AUG-1997; 97US-0056637.
PR 22-AUG-1997; 97US-0056662.
PR 22-AUG-1997; 97US-0056664.
PR 22-AUG-1997; 97US-0056845.
PR 22-AUG-1997; 97US-0056862.
PR 22-AUG-1997; 97US-0056864.
PR 22-AUG-1997; 97US-0056872.
PR 22-AUG-1997; 97US-0056874.
PR 22-AUG-1997; 97US-0056875.
PR 22-AUG-1997; 97US-0056876.
PR 22-AUG-1997; 97US-0056877.
PR 22-AUG-1997; 97US-0056878.
PR 22-AUG-1997; 97US-0056879.
PR 22-AUG-1997; 97US-0056880.
PR 22-AUG-1997; 97US-0056881.
PR 22-AUG-1997; 97US-0056882.
PR 22-AUG-1997; 97US-0056884.
PR 22-AUG-1997; 97US-0056886.
PR 22-AUG-1997; 97US-0056887.
PR 22-AUG-1997; 97US-0056888.
PR 22-AUG-1997; 97US-0056889.
PR 22-AUG-1997; 97US-0056892.
PR 22-AUG-1997; 97US-0056893.
PR 22-AUG-1997; 97US-0056894.
PR 22-AUG-1997; 97US-0056903.
PR 22-AUG-1997; 97US-0056908.
PR 22-AUG-1997; 97US-0056909.
PR 22-AUG-1997; 97US-0056910.
PR 22-AUG-1997; 97US-0056911.
PR 05-SEP-1997; 97US-0057650.
PR 05-SEP-1997; 97US-0057761.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Bednarik DP, Brewer LA, Carter KC, Duan R, Ebner R, Endress GA;
PI Feng P, Ferrie AM, Fischer CL, Graves KA, Greene JM, Hu JS;
PI Kyaw H, Lafleur DW, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA;
PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z;
XX
DR WPI; 1998-609887/51.
XX
PT New isolated human genes and the secreted polypeptides they encode
PT - useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders
XX
PS Example 16; Page 226; 721pp; English.
XX
CC The invention relates to 70 novel genes and their fragments (nucleic
CC acid sequences: AAV34154-V34276; amino acid sequences AAW75057-W75179)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 70
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAV34154 for described uses). The genes can be used to generate
CC fusion proteins by linking to the gene to a sequence encoding human
CC immunoglobulin Fc portion (AAV34145) for increasing the stability of the
CC fused protein as compared to the secreted protein only. Genes encoding
CC the secreted proteins can be used for high-throughput assays for
CC biological activities. Expression of the genes can be driven by a range
CC of promoter active in eukaryotic cells. Primers AAV34151-V34152 are used
CC to amplify the nuclear factor kappa-B (NF-kB) gene promoter (AAV34153) to
CC generate a construct for identifying proteins involved in immune
CC responses.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 19; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

RESULT 2
AAV59508
ID AAV59508 standard; DNA; 12 BP.
XX
AC AAV59508;
XX
DT 02-FEB-1999 (first entry)
XX
DE Upstream primer for nuclear factor kappa-B gene promoter.
XX

KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9839448-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US04493.
XX
PR 02-OCT-1997; 97US-0061060.
PR 07-MAR-1997; 97US-0038621.
PR 07-MAR-1997; 97US-0040161.
PR 07-MAR-1997; 97US-0040162.
PR 07-MAR-1997; 97US-0040163.
PR 07-MAR-1997; 97US-0040333.
PR 07-MAR-1997; 97US-0040334.
PR 07-MAR-1997; 97US-0040336.
PR 07-MAR-1997; 97US-0040626.
PR 11-APR-1997; 97US-0043311.
PR 11-APR-1997; 97US-0043312.
PR 11-APR-1997; 97US-0043313.
PR 11-APR-1997; 97US-0043314.
PR 11-APR-1997; 97US-0043568.
PR 11-APR-1997; 97US-0043569.
PR 11-APR-1997; 97US-0043576.
PR 11-APR-1997; 97US-0043578.
PR 11-APR-1997; 97US-0043580.
PR 11-APR-1997; 97US-0043669.
PR 11-APR-1997; 97US-0043670.
PR 11-APR-1997; 97US-0043671.
PR 11-APR-1997; 97US-0043672.
PR 11-APR-1997; 97US-0043674.
PR 23-MAY-1997; 97US-0047492.
PR 23-MAY-1997; 97US-0047500.
PR 23-MAY-1997; 97US-0047501.
PR 23-MAY-1997; 97US-0047502.
PR 23-MAY-1997; 97US-0047503.
PR 23-MAY-1997; 97US-0047581.
PR 23-MAY-1997; 97US-0047582.
PR 23-MAY-1997; 97US-0047583.
PR 23-MAY-1997; 97US-0047584.
PR 23-MAY-1997; 97US-0047585.
PR 23-MAY-1997; 97US-0047586.
PR 23-MAY-1997; 97US-0047587.
PR 23-MAY-1997; 97US-0047588.
PR 23-MAY-1997; 97US-0047589.
PR 23-MAY-1997; 97US-0047590.
PR 23-MAY-1997; 97US-0047592.
PR 23-MAY-1997; 97US-0047593.
PR 23-MAY-1997; 97US-0047594.
PR 23-MAY-1997; 97US-0047595.
PR 23-MAY-1997; 97US-0047596.
PR 23-MAY-1997; 97US-0047597.
PR 23-MAY-1997; 97US-0047598.
PR 23-MAY-1997; 97US-0047599.
PR 23-MAY-1997; 97US-0047600.
PR 23-MAY-1997; 97US-0047601.
PR 23-MAY-1997; 97US-0047612.
PR 23-MAY-1997; 97US-0047613.
PR 23-MAY-1997; 97US-0047614.
PR 23-MAY-1997; 97US-0047615.
PR 23-MAY-1997; 97US-0047617.
PR 23-MAY-1997; 97US-0047618.
PR 23-MAY-1997; 97US-0047632.
PR 23-MAY-1997; 97US-0047633.
PR 06-JUN-1997; 97US-0048964.
PR 06-JUN-1997; 97US-0048974.
PR 13-JUN-1997; 97US-0049610.
PR 08-JUL-1997; 97US-0051926.
PR 16-JUL-1997; 97US-0052874.
PR 18-AUG-1997; 97US-0055724.
PR 22-AUG-1997; 97US-0056630.
PR 22-AUG-1997; 97US-0056631.
PR 22-AUG-1997; 97US-0056632.
PR 22-AUG-1997; 97US-0056636.
PR 22-AUG-1997; 97US-0056637.
PR 22-AUG-1997; 97US-0056662.
PR 22-AUG-1997; 97US-0056664.
PR 22-AUG-1997; 97US-0056845.
PR 22-AUG-1997; 97US-0056862.
PR 22-AUG-1997; 97US-0056864.
PR 22-AUG-1997; 97US-0056872.
PR 22-AUG-1997; 97US-0056874.
PR 22-AUG-1997; 97US-0056875.
PR 22-AUG-1997; 97US-0056876.
PR 22-AUG-1997; 97US-0056877.
PR 22-AUG-1997; 97US-0056878.
PR 22-AUG-1997; 97US-0056879.
PR 22-AUG-1997; 97US-0056880.
PR 22-AUG-1997; 97US-0056881.
PR 22-AUG-1997; 97US-0056882.
PR 22-AUG-1997; 97US-0056884.
PR 22-AUG-1997; 97US-0056886.
PR 22-AUG-1997; 97US-0056887.
PR 22-AUG-1997; 97US-0056888.
PR 22-AUG-1997; 97US-0056889.
PR 22-AUG-1997; 97US-0056892.
PR 22-AUG-1997; 97US-0056893.
PR 22-AUG-1997; 97US-0056894.
PR 22-AUG-1997; 97US-0056903.
PR 22-AUG-1997; 97US-0056908.
PR 22-AUG-1997; 97US-0056909.
PR 22-AUG-1997; 97US-0056910.
PR 22-AUG-1997; 97US-0056911.
PR 05-SEP-1997; 97US-0057650.
PR 05-SEP-1997; 97US-0057669.
PR 05-SEP-1997; 97US-0057761.
PR 12-SEP-1997; 97US-0058785.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Bednarik DP, Brewer LA, Carter KC, Duan R, Ebner R, Endress GA;
PI Feng P, Ferrie AM, Fischer CL, Florence KA, Greene JM, Hu JS;
PI Kyaw H, Lafleur DW, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA;
PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z;
XX
DR WPI; 1998-506364/43.
XX
PT New isolated human genes and the secreted polypeptide(s) they encode
PT - useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders
XX
PS Example 16; Page 226; 721pp; English.
XX
CC The invention relates to 186 novel genes and their fragments (nucleic
CC acid sequences: AAV59511-V59812; amino acid sequences AAW74731-W75026)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 186
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAV59511 for described uses). The genes can be used to generate
CC fusion proteins by linking to the gene to a sequence encoding human
CC immunoglobulin Fc portion (AAV59502) for increasing the stability of the
CC fused protein as compared to the secreted protein only. Genes encoding
CC the secreted proteins can be used for high-throughput assays for

```
CC   biological activities. Expression of the genes can be driven by a range
CC   of promoter active in eukaryotic cells.  Primers AAV59508-V59509 are used
CC   to amplify the nuclear factor kappa-B (NF-kB) gene promoter (AAV59510) to
CC   generate a construct for identifying proteins involved in immune
CC   responses.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 19;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   3
AAV34283
ID   AAV34283 standard; DNA; 12 BP.
XX
AC   AAV34283;
XX
DT   29-JAN-1999  (first entry)
XX
DE   Upstream primer for nuclear factor kappa-B gene promoter.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9840483-A2.
XX
PD   17-SEP-1998.
XX
PF   12-MAR-1998;   98WO-US04858.
XX
PR   19-DEC-1997;   97US-0068368.
PR   14-MAR-1997;   97US-0040710.
PR   14-MAR-1997;   97US-0040762.
PR   30-MAY-1997;   97US-0048100.
PR   30-MAY-1997;   97US-0048189.
PR   30-MAY-1997;   97US-0048357.
PR   30-MAY-1997;   97US-0050934.
PR   06-JUN-1997;   97US-0048970.
PR   05-SEP-1997;   97US-0057765.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ferrie AM,  Fischer CL,  Gentz RL,  Greene JM,  Kyaw H;
PI   Li H,  Li Y,  Moore PA,  Rosen CA,  Ruben SM,  Soppet DR;
PI   Wei YF,  Young PE,  Zeng Z;
XX
DR   WPI; 1998-520811/44.
XX
PT   Isolated human poly:nucleotide(s) encoding secretory peptide(s) -
PT   used to develop products for the diagnosis and treatment of e.g.
PT   inflammation, cancers, CNS disorders or immune system disorders
XX
PS   Example 16; Page 95; 201pp; English.
XX
CC   The invention relates to 28 novel genes and their fragments (nucleic
CC   acid sequences: AAV34286-V34325; amino acid sequences AAW75196-W75235)
CC   which are useful for preventing, treating or ameliorating  medical
CC   conditions e.g. by protein or gene therapy.  Also, pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the new polynucleotides. Specific uses are described for each of the 28
CC   polynucleotides, based on which tissues they are most highly expressed in
CC   (see AAV34286 for described uses).  The genes can be used to generate
CC   fusion proteins by linking to the gene to a sequence encoding human
CC   immunoglobulin Fc portion (AAV34277) for increasing the stability of the
CC   fused protein as compared to the secreted protein only.  Genes encoding
CC   the secreted proteins can be used for high-throughput assays for
CC   biological activities. Expression of the genes can be driven by a range
CC   of promoter active in eukaryotic cells.  Primers AAV34283-V34284 are used
CC   to amplify the nuclear factor kappa-B (NF-kB) gene promoter (AAV34285) to
CC   generate a construct for identifying proteins involved in immune
CC   responses.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 19;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   4
AAV69608
ID   AAV69608 standard; DNA; 12 BP.
XX
AC   AAV69608;
XX
DT   28-JAN-1999  (first entry)
XX
DE   Upstream primer for nuclear factor kappa-B gene promoter.
XX
KW   Secreted protein; gene therapy; protein therapy; diagnosis; treatment;
KW   central nervous system; CNS; immune system; cancer; trauma; liver;
KW   reproductive disorder; congenital malformation; degenerative disease;
KW   inflammatory disease; neoplasia; metabolic disorder; testis; placenta;
KW   brain; T cell; spleen; lung; heart; rhabdomyosarcoma; endocrine system;
KW   endocrinopathy; endocrine polyglandular syndrome; endocrinoma; sepsis;
KW   endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone;
KW   primer; nuclear factor kappa-B; NF-kB; ds.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9845712-A2.
XX
PD   15-OCT-1998.
XX
PF   07-APR-1998;   98WO-US06801.
XX
PR   30-MAY-1997;   97US-0048184.
PR   08-APR-1997;   97US-0042726.
PR   08-APR-1997;   97US-0042727.
PR   08-APR-1997;   97US-0042728.
PR   08-APR-1997;   97US-0042754.
PR   08-APR-1997;   97US-0042825.
PR   30-MAY-1997;   97US-0048068.
PR   30-MAY-1997;   97US-0048070.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Feng P,  Ni J,  Rosen CA,  Ruben SM,  Yu G;
XX
DR   WPI; 1998-594496/50.
XX
PT   New isolated human genes and secreted polypeptide(s) they encode -
PT   useful for the diagnosis and treatment of e.g. cancers, CNS
```

PT disorders, immune system disorders, inflammatory disease and
PT bacterial infections
XX
PS Example 16; Page 83; 142pp; English.
XX
CC The invention relates to 20 novel genes and their fragments (AAV69611 to
CC AAV69630) and corresponding secreted proteins (AAW83931 to AAW83950)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein of gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the
CC polynucleotides. Specific uses are based on which tissues they are most
CC highly expressed in (see AAV69611 for described uses). The genes can be
CC used to generate fusion proteins by linking to the gene, a sequence
CC encoding human immunoglobulin Fc portion (AAV69602) for increasing the
CC stability of the fused protein as compared to the secreted protein only.
CC Genes encoding the secreted proteins can be used for high-throughput
CC assays for biological activities. Expression of the genes can be driven
CC by a range of promoter active in eukaryotic cells. Primers
CC AAV69608-V69609 are used to amplify the nuclear factor kappa-B (NF-kB)
CC gene promoter (AAV69610) to generate a construct for identifying proteins
CC involved in immune responses.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 19; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

RESULT 5
AAZ32078
ID AAZ32078 standard; DNA; 12 BP.
XX
AC AAZ32078;
XX
DT 10-JAN-2000 (first entry)
XX
DE Nuclear factor KB binding site.
XX
KW Human; METH1; METH2; anti-angiogenic; metalloprotease thrombospondin;
KW cancer; diagnosis; hyperproliferative disorder; autoimmune disease;
KW angiogenesis inhibitor; abnormal wound healing; inflammation;
KW rheumatoid arthritis; psoriasis; endometrial bleeding disorder;
KW diabetic retinopathy; macula degeneration; haemangioma; detection;
KW arterial-venous malformation; immune deficiency; ss.
XX
OS Homo sapiens.
XX
PN WO9937660-A1.
XX
PD 29-JUL-1999.
XX
PF 22-JAN-1999; 99WO-US01313.
XX
PR 23-JAN-1998; 98US-0072298.
PR 28-AUG-1998; 98US-0098539.
XX
PA (IRUE/) IRUELA-ARISPE L.
PA (HAST/) HASTINGS G A.
PA (RUBE/) RUBEN S M.
XX
PI Iruela-Arispe L, Hastings GA, Ruben SM;
XX
DR WPI; 1999-590684/50.
XX
PT New isolated metalloprotease thrombospondin polypeptides, useful for
PT treating hyperproliferative disorders, cancers or autoimmune disorders
PT -
XX
PS Example 19; Page 158; 457pp; English.
XX
CC AAZ32000 and AAZ32001 encode, and AAY49501 and AAY49502 represent, human
CC metalloprotease thrombospondin (METH) proteins METH1 and METH2
CC respectively. METH1 and METH2 have been found to be potent inhibitors of
CC angiogenesis both in vitro and in vivo. They can be used for treating
CC cancer and other disorders related to angiogenesis including abnormal
CC wound healing, inflammation, rheumatoid arthritis, psoriasis,
CC endometrial bleeding disorders, diabetic retinopathy, some forms of
CC macula degeneration, haemangiomas, and arterial-venous malformations.
CC They may be useful in treating deficiencies or disorders of the immune
CC system, by activating or inhibiting the proliferation, differentiation,
CC or mobilisation (chemotaxis) of immune cells. The etiology of these
CC immune deficiencies or disorders may be genetic, somatic, such as
CC cancer or some autoimmune disorders, acquired (e.g. by chemotherapy or
CC toxins), or infectious. They can also be used to treat inflammatory
CC conditions, both chronic and acute conditions. The products can also be
CC used for detection and diagnosis. AAZ32002 to AAZ32080, and AAY49503 to
CC AAY49511 represent sequences given in the exemplification of the present
CC invention.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 20; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

RESULT 6
AAZ24808
ID AAZ24808 standard; DNA; 12 BP.
XX
AC AAZ24808;
XX
DT 02-DEC-1999 (first entry)
XX
DE Nuclear factor kappa-B binding site sequence.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ss;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9947540-A1.
XX
PD 23-SEP-1999.
XX
PF 18-MAR-1999; 99WO-US05804.
XX
PR 19-MAR-1998; 98US-0078563.
PR 19-MAR-1998; 98US-0078566.
PR 19-MAR-1998; 98US-0078573.
PR 19-MAR-1998; 98US-0078574.
PR 19-MAR-1998; 98US-0078576.
PR 19-MAR-1998; 98US-0078577.
PR 19-MAR-1998; 98US-0078578.
PR 19-MAR-1998; 98US-0078579.
PR 19-MAR-1998; 98US-0078581.
PR 01-APR-1998; 98US-0080312.

PR 01-APR-1998; 98US-0080313.
PR 01-APR-1998; 98US-0080314.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Rosen CA, Yu G, Young PE, Feng P, Soppet DR;
PI Wei Y, Endress GA, Duan RD, Kyaw H, Ebner R, Lafleur DW;
PI Olsen HS, Shi Y, Moore PA;
XX
DR WPI; 1999-562050/47.
XX
PT New isolated human genes, useful for diagnosis and treatment of e.g.
PT cancers, neurological disorders, immune diseases, inflammation or blood
PT disorders -
XX
PS Example 16; Page 262; 484pp; English.
XX
CC The invention relates to 95 novel genes and their fragments (nucleic
CC acid sequences: AAZ24811-Z24907; amino acid sequences AAY41308-Y41404)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 95
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAZ24811 for described uses). The genes can be used to generate
CC fusion proteins by linking to the gene to a sequence encoding human
CC immunoglobulin Fc portion (AAZ24802) for increasing the stability of the
CC fused protein as compared to the secreted protein only. Genes encoding
CC the secreted proteins can be used for high-throughput assays for
CC biological activities. Expression of the genes can be driven by a range
CC of promoter active in eukaryotic cells. This sequence represents the
CC nuclear factor kappa-B (NF-kB) binding site sequence which is used to
CC generate a construct (AAZ24810) for identifying proteins involved in
CC immune responses.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 20; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

RESULT 7
AAZ09781
ID AAZ09781 standard; DNA; 12 BP.
XX
AC AAZ09781;
XX
DT 23-NOV-1999 (first entry)
XX
DE Nuclear factor kappaB binding site DNA motif.
XX
KW Secreted protein; human; gene therapy; diagnosis; treatment; cancer;
KW protein therapy; tumor; neurodegenerative disorder; blood disorder; AIDS;
KW developmental abnormality; leukemia; immune system; autoimmune disease;
KW hepatic disease; renal disease; inflammation; allergy; schizophrenia;
KW Alzheimer's disease; cognitive disorder; arthritis; infection; psoriasis;
KW transplant rejection; diabetes; asthma; sepsis; acne; metabolic disorder;
KW cardiovascular disorder; food additive; preservative; NF-kappaB;
KW nuclear factor kappaB; ss.
XX
OS Unidentified.
XX
PN WO9946289-A1.
XX
PD 16-SEP-1999.
XX
PF 11-MAR-1999; 99WO-US05721.
XX
PR 12-MAR-1998; 98US-0077686.
PR 12-MAR-1998; 98US-0077687.
PR 12-MAR-1998; 98US-0077696.
PR 12-MAR-1998; 98US-0077714.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ferrie AM, Rosen CA, Florence C, Young PE, Yu G, Ni J;
XX
DR WPI; 1999-551363/46.
XX
PT New isolated human genes, useful for diagnosis and treatment of, e.g.
PT cancers -
XX
PS Example 16; Page 148; 306pp; English.
XX
CC This invention describes novel human genes and the secreted proteins they
CC encode. The polynucleotides and their corresponding secreted polypeptides
CC are useful for preventing, treating or ameliorating medical conditions
CC e.g. by protein or gene therapy. Also pathological conditions can be
CC diagnosed by determining the amount of the new polypeptides in a sample
CC or by determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the polynucleotides of the
CC invention, based on which tissues they are most highly expressed in, and
CC include developing products for the diagnosis or treatment of cancer,
CC tumors, neurodegenerative disorders, developmental abnormalities, blood
CC disorders, leukemias, diseases of the immune system, autoimmune diseases,
CC hepatic and renal disease, inflammation, allergies, Alzheimer's and
CC cognitive disorders, schizophrenia, arthritis, infections, AIDS,
CC transplant rejection, diabetes, asthma, sepsis, acne, psoriasis,
CC cardiovascular disorders, and metabolic disorders. The polypeptides or
CC polynucleotides can also be used as food additives or preservatives. The
CC polypeptides are also useful for identifying their binding partners. This
CC sequence represents a nuclear factor kappaB (NF-kappaB) binding site
CC motif which is used for the construction of a NF-kappaB/SV40 promoter
CC construct which is used in the method of the invention.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 20; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

RESULT 8
AAZ00407
ID AAZ00407 standard; DNA; 12 BP.
XX
AC AAZ00407;
XX
DT 04-OCT-1999 (first entry)
XX
DE Human NF-KappaB binding site DNA motif.
XX
KW Secreted protein; human; treatment; diagnosis; therapy; cancer; tumour;
KW neurodegenerative disorder; developmental abnormality; blood disorder;
KW fetal deficiency; blood disorder; leukemia; immune system; inflammation;
KW autoimmune disease; hepatic disease; renal disease; allergy; restenosis;
KW ischemic shock; Alzheimer's disease; cognitive disorder; schizophrenia;
KW cardiovascular disorder; wound healing; stroke; arthritis; obesity;
KW asthma; sepsis; acne; psoriasis; transplant rejection; infection; AIDS;
KW metabolic disorder; NF-kappaB; ss.
XX
OS Homo sapiens.
XX
PN WO9938881-A1.

```
XX
PD   05-AUG-1999.
XX
PF   27-JAN-1999;   99WO-US01621.
XX
PR   30-JAN-1998;   98US-0073170.
PR   30-JAN-1998;   98US-0073159.
PR   30-JAN-1998;   98US-0073160.
PR   30-JAN-1998;   98US-0073161.
PR   30-JAN-1998;   98US-0073162.
PR   30-JAN-1998;   98US-0073164.
PR   30-JAN-1998;   98US-0073165.
PR   30-JAN-1998;   98US-0073167.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Carter KC,  Endress GA,  Feng P,  Ferrie AM,  Florence C;
PI   Florence KA,  Janat F,  Ni J,  Rosen CA,  Ruben SM;
PI   Soppet DR,  Young P,  Yu G;
XX
DR   WPI; 1999-469315/39.
XX
PT   New isolated human genes and the secreted polypeptides they encode
PT   useful in, e.g. treatment of Alzheimer's
XX
PS   Example 16; Page 255; 393pp; English.
XX
CC   This invention describes novel human genes and the secreted proteins they
CC   encode. The polynucleotides and their corresponding secreted polypeptides
CC   are useful for preventing, treating or ameliorating medical conditions
CC   e.g. by protein or gene therapy. Also pathological conditions can be
CC   diagnosed by determining the amount of the new polypeptides in a sample
CC   or by determining the presence of mutations in the new polynucleotides.
CC   Specific uses are described for each of the 67 polynucleotides of the
CC   invention, based on which tissues they are most highly expressed in, and
CC   include developing products for the diagnosis or treatment of cancer,
CC   tumours, neurodegenerative disorders, developmental abnormalities and
CC   fetal deficiencies, blood disorders, leukemias, diseases of the immune
CC   system, autoimmune diseases, hepatic and renal disease, inflammation,
CC   allergies, ischemic shock, Alzheimer's and cognitive disorders,
CC   schizophrenia, restenosis, cardiovascular disorders, wound healing,
CC   stroke, arthritis, obesity, asthma, sepsis, acne, psoriasis, transplant
CC   rejection, metabolic disorders, infections and AIDS. The polypeptides
CC   are also useful for identifying their binding partners. This sequence
CC   represents the human NF-kappaB binding site DNA motif which is used to
CC   describe the method of the invention.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 ggggactttccc 12


RESULT   9
AAZ00799
ID   AAZ00799 standard; DNA; 12 BP.
XX
AC   AAZ00799;
XX
DT   11-OCT-1999  (first entry)
XX
DE   NF-kappaB DNA binding site motif.
XX
KW   Secreted protein; prevention; treatment; protein therapy; gene therapy;
KW   diagnosis; cancer; tumour; neurodegenerative disorder; blood disorder;
KW   developmental abnormality; fetal deficiency; leukemia; autoimmune; acne;
KW   hepatic disease; renal disease; lymphoma; inflammation; allergy; asthma;
KW   Alzheimer's disease; cognitive disorder; schizophrenia; obesity; sepsis;
KW   osteoporosis; arthritis; infection; AIDS; connective tissue disorder;
KW   transplant rejection; diabetes; psoriasis; cardiovascular disorder;
KW   reproductive disorder; food additive; food preservative; human;
KW   NF-kappaB; nuclear factor kappaB; ss.
XX
OS   Homo sapiens.
XX
PN   WO9940100-A1.
XX
PD   12-AUG-1999.
XX
PF   04-FEB-1999;   99WO-US02293.
XX
PR   09-FEB-1998;   98US-0074341.
PR   09-FEB-1998;   98US-0074037.
PR   09-FEB-1998;   98US-0074118.
PR   09-FEB-1998;   98US-0074141.
PR   09-FEB-1998;   98US-0074157.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Kyaw H,  Lafleur DW,  Moore PA,  Rosen CA,  Ruben SM;
PI   Shi Y,  Wei Y;
XX
DR   WPI; 1999-479426/40.
XX
PT   New isolated human genes potentially useful for, e.g. developmental
PT   abnormalities and fetal deficiencies
XX
PS   Example 16; Page 173; 263pp; English.
XX
CC   This invention describes novel isolated human genes and the secreted
CC   proteins they encode. The polynucleotides and their corresponding
CC   secreted polypeptides are useful for preventing, treating or ameliorating
CC   medical conditions e.g. by protein or gene therapy. Also pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the new polynucleotides. Specific uses are described for the
CC   polynucleotides of the invention based on which tissues they are most
CC   highly expressed in, and include developing products for the diagnosis or
CC   treatment of cancer, tumours, neurodegenerative disorders, developmental
CC   abnormalities and fetal deficiencies, blood disorders, leukemias,
CC   diseases of the immune system, autoimmune diseases, hepatic and renal
CC   disease, lymphomas, inflammation, allergies, Alzheimer's and cognitive
CC   disorders, schizophrenia, obesity, osteoporosis, arthritis, infections,
CC   AIDS, connective tissue disorders, transplant rejection, diabetes,
CC   asthma, sepsis, acne, psoriasis, cardiovascular disorders, and
CC   reproductive disorders. The polypeptides or polynucleotides can also be
CC   used as food additives or preservatives. The polypeptide are also useful
CC   for identifying their binding partners. This sequence represents a DNA
CC   binding motif from the nuclear factor KappaB (NF-kappaB) which is used
CC   to describe the method of the invention.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 ggggactttccc 12


RESULT   10
AAZ06216
ID   AAZ06216 standard; DNA; 12 BP.
XX
AC   AAZ06216;
XX
DT   30-SEP-1999  (first entry)
```

```
XX
DE   Nuclear factor kapp-B binding site sequence.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9935158-A1.
XX
PD   15-JUL-1999.
XX
PF   06-JAN-1999;   99WO-US00108.
XX
PR   07-JAN-1998;   98US-0070704.
PR   07-JAN-1998;   98US-0070657.
PR   07-JAN-1998;   98US-0070658.
PR   07-JAN-1998;   98US-0070692.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Brewer LA,  Duan RD,  Ebner R,  Lafleur DW,  Ni J;
PI   Olsen HS,  Rosen CA,  Ruben SM,  Soppet DR;
XX
DR   WPI; 1999-444190/37.
XX
PT   New isolated human genes and the secreted polypeptides they encode
XX
PS   Example 16; Page 126; 227pp; English.
XX
CC   The invention relates to 36 novel genes and their fragments (nucleic
CC   acid sequences: AAZ06219-Z06263; amino acid sequences AAY38386-Y38498)
CC   which are useful for preventing, treating or ameliorating medical
CC   conditions e.g. by protein or gene therapy.  Also, pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the new polynucleotides. Specific uses are described for each of the 36
CC   polynucleotides, based on which tissues they are most highly expressed in
CC   (see AAZ06219 for described uses).  The genes can be used to generate
CC   fusion proteins by linking to the gene to a sequence encoding human
CC   immunoglobulin Fc portion (AAZ06210) for increasing the stability of the
CC   fused protein as compared to the secreted protein only.  Genes encoding
CC   the secreted proteins can be used for high-throughput assays for
CC   biological activities. Expression of the genes can be driven by a range
CC   of promoter active in eukaryotic cells.  This sequence represents the
CC   nuclear factor kappa-B (NF-kB) binding site sequence which is used to
CC   generate a construct (AAZ06218) for identifying proteins involved in
CC   immune responses.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 ggggactttccc 12


RESULT  11
AAX97913
ID   AAX97913 standard; DNA; 12 BP.
XX
AC   AAX97913;
XX
DT   17-SEP-1999  (first entry)
XX
DE   Nuclear factor kappa-B binding site sequence.
XX
KW   Human; secreted protein; cancer; tumour; developmental abnormality;
KW   foetal deficiency; blood disorder; immune system disorder; inflammation;
KW   autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW   schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW   atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW   digestive disorder; endocrine disorder; infection; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO9931117-A1.
XX
PD   24-JUN-1999.
XX
PF   17-DEC-1998;   98WO-US27059.
XX
PR   19-DEC-1997;   97US-0068369.
PR   18-DEC-1997;   97US-0068006.
PR   18-DEC-1997;   97US-0068007.
PR   18-DEC-1997;   97US-0068008.
PR   18-DEC-1997;   97US-0068053.
PR   18-DEC-1997;   97US-0068054.
PR   18-DEC-1997;   97US-0068057.
PR   18-DEC-1997;   97US-0068064.
PR   18-DEC-1997;   97US-0070923.
PR   19-DEC-1997;   97US-0068169.
PR   19-DEC-1997;   97US-0068365.
PR   19-DEC-1997;   97US-0068367.
PR   19-DEC-1997;   97US-0068368.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Carter KC,  Duan RD,  Feng P,  Ferrie AM,  Florence C;
PI   Florence K,  Greene JM,  Janat F,  Kyaw H,  Moore PA;
PI   Ni J,  Rosen CA,  Ruben SM,  Shi Y,  Soppet DR,  Wei Y;
PI   Yu G;
XX
DR   WPI; 1999-418749/35.
XX
PT   New isolated human genes encoding secreted polypeptides
XX
PS   Example 16; Page 247; 537pp; English.
XX
CC   AAX97916 to AAX98029 represent 110 isolated human secreted protein
CC   genes. AAY36224 to AAY36727 represent the secreted proteins encoded by
CC   the 110 human genes. The genes and their corresponding secreted
CC   polypeptides are useful for preventing, treating or ameliorating medical
CC   conditions, e.g. by protein or gene therapy. Also pathological conditions
CC   can be diagnosed by determining the amount of the new polypeptides in a
CC   sample or by determining the presence of mutations in the new genes.
CC   Specific uses are described for each of the 110 genes, based on which
CC   tissues they are most highly expressed in, and include developing
CC   products for the diagnosis or treatment of cancer, tumours, developmental
CC   abnormalities and foetal deficiencies, blood disorders, diseases of the
CC   immune system, autoimmune diseases, inflammation, allergies, Alzheimer's
CC   and cognitive disorders, schizophrenia, arthritis, asthma, psoriasis,
CC   sepsis, skin disorders, atherosclerosis, diabetes, cardiovascular
CC   disorders, kidney disorders, digestive/endocrine disorders, infections
CC   and AIDS. The polypeptides are also useful for identifying their binding
CC   partners. The sequences given in AAX97907 to AAX97915 and AAY36223 are
CC   used in the  exemplification of the present invention.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  12
AAX79008
ID   AAX79008 standard; DNA; 12 BP.
XX
AC   AAX79008;
XX
DT   17-AUG-1999  (first entry)
XX
DE   Upstream primer for nuclear factor kappa-B gene promoter.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal; ss;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9919339-A1.
XX
PD   22-APR-1999.
XX
PF   08-OCT-1998;   98WO-US21142.
XX
PR   09-OCT-1997;   97US-0071498.
PR   09-OCT-1997;   97US-0061463.
PR   09-OCT-1997;   97US-0061527.
PR   09-OCT-1997;   97US-0061529.
PR   09-OCT-1997;   97US-0061532.
PR   09-OCT-1997;   97US-0061536.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Brewer LA,  Duan R,  Ebner R,  Ferrie AM,  Florence C;
PI   Florence KA,  Greene JM,  Olsen HS,  Rosen CA,  Ruben SM;
PI   Young PE,  Yu G;
XX
DR   WPI; 1999-277587/23.
XX
PT   New isolated human genes and the secreted polypeptides they encode
XX
PS   Example 16; Page 138; 226pp; English.
XX
CC   The invention relates to 53 novel genes and their fragments (nucleic
CC   acid sequences: AAX79011-X79064; amino acid sequences AAY14411-Y14464)
CC   which are useful for preventing, treating or ameliorating  medical
CC   conditions e.g. by protein or gene therapy.  Also, pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the new polynucleotides. Specific uses are described for each of the 53
CC   polynucleotides, based on which tissues they are most highly expressed in
CC   (see AAX79011 for described uses).  The genes can be used to generate
CC   fusion proteins by linking to the gene to a sequence encoding human
CC   immunoglobulin Fc portion (AAX79002) for increasing the stability of the
CC   fused protein as compared to the secreted protein only.  Genes encoding
CC   the secreted proteins can be used for high-throughput assays for
CC   biological activities. Expression of the genes can be driven by a range
CC   of promoter active in eukaryotic cells.  This sequence represents the
CC   nuclear factor kappa-B (NF-kB) binding site sequence which is used to
CC   generate a construct (AAX79010) for identifying proteins involved in
CC   immune responses.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

  Query Match            100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  13
AAX84930
ID   AAX84930 standard; DNA; 12 BP.
XX
AC   AAX84930;
XX
DT   30-JUL-1999  (first entry)
XX
DE   Nuclear factor kapp-B binding site sequence.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9924836-A1.
XX
PD   20-MAY-1999.
XX
PF   04-NOV-1998;   98WO-US23435.
XX
PR   17-NOV-1997;   97US-0066100.
PR   07-NOV-1997;   97US-0064900.
PR   07-NOV-1997;   97US-0064908.
PR   07-NOV-1997;   97US-0064911.
PR   07-NOV-1997;   97US-0064912.
PR   07-NOV-1997;   97US-0064983.
PR   07-NOV-1997;   97US-0064984.
PR   07-NOV-1997;   97US-0064985.
PR   07-NOV-1997;   97US-0064987.
PR   07-NOV-1997;   97US-0064988.
PR   17-NOV-1997;   97US-0066090.
PR   17-NOV-1997;   97US-0066094.
PR   17-NOV-1997;   97US-0066095.
PR   17-NOV-1997;   97US-0066089.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Carter KC,  Ebner R,  Endress GA,  Feng P,  Janat F;
PI   Kyaw H,  Lafleur DW,  Moore PA,  Ni J,  Olsen HS,  Rosen CA;
PI   Ruben SM,  Shi Y,  Soppet DR,  Wei Y;
XX
DR   WPI; 1999-337740/28.
XX
PT   New human secreted proteins and coding sequences useful for treating
PT   disorders of the immune system and hyperproliferative disorders
XX
PS   Example 16; Page 259; 507pp; English.
XX
CC   The invention relates to 125 novel genes and their fragments (nucleic
CC   acid sequences: AAX84933-X85057; amino acid sequences AAY27567-Y27933)
CC   which are useful for preventing, treating or ameliorating  medical
CC   conditions e.g. by protein or gene therapy.  Also, pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the new polynucleotides. Specific uses are described for each of the 125
```

```
CC   polynucleotides, based on which tissues they are most highly expressed in
CC   (see AAX84933 for described uses).  The genes can be used to generate
CC   fusion proteins by linking to the gene to a sequence encoding human
CC   immunoglobulin Fc portion (AAX84924) for increasing the stability of the
CC   fused protein as compared to the secreted protein only.  Genes encoding
CC   the secreted proteins can be used for high-throughput assays for
CC   biological activities. Expression of the genes can be driven by a range
CC   of promoter active in eukaryotic cells.  This sequence represents the
CC   nuclear factor kappa-B (NF-kB) binding site sequence which is used to
CC   generate a construct (AAX84932) for identifying proteins involved in
CC   immune responses.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  14
AAX37366
ID   AAX37366 standard; DNA; 12 BP.
XX
AC   AAX37366;
XX
DT   06-JUL-1999  (first entry)
XX
DE   Human NF-kappaB promoter element PCR primer 1.
XX
KW   Human; secreted protein; prevention; treatment; protein therapy;
KW   gene therapy; diagnosis; cancer; tumour; neurodegenerative disorder;
KW   developmental abnormality; foetal deficiency; blood disorder; lymphoma;
KW   leukemia; immune system disorder; autoimmune disease; hepatic disease;
KW   renal disease; inflammation; allergy; asthma; sepsis; diabetes; AIDS;
KW   Alzheimer's disease; cognitive disorder; schizophrenia; osteoporosis;
KW   arthritis; psoriasis; digestive; endocrine; infection; promoter;
KW   PCR primer; NF-kappaB; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9909155-A1.
XX
PD   25-FEB-1999.
XX
PF   18-AUG-1998;   98WO-US17044.
XX
PR   16-JUN-1998;   98US-0092956.
PR   15-JUL-1998;   98US-0092956.
PR   19-AUG-1997;   97US-0056368.
PR   19-AUG-1997;   97US-0056369.
PR   19-AUG-1997;   97US-0056535.
PR   19-AUG-1997;   97US-0056555.
PR   19-AUG-1997;   97US-0056556.
PR   19-AUG-1997;   97US-0056628.
PR   19-AUG-1997;   97US-0056629.
PR   19-AUG-1997;   97US-0056726.
PR   19-AUG-1997;   97US-0056728.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Brewer LA,  Duan R,  Ebner R,  Endress GA,  Feng P;
PI   Florence C,  Florence KA,  Komatsoulis GA,  Lafleur DW;
PI   Moore PA,  Olsen HS,  Rosen CA,  Ruben SM,  Shi Y,  Soppet DR;
PI   Young PE;
XX
DR   WPI; 1999-190160/16.
XX
PT   New isolated human genes and the secreted polypeptides they encode
PT   - useful for diagnosis and treatment of e.g. cancers, neurological
PT   disorders, immune diseases, inflammation or blood disorders
XX
PS   Example 16; Page 164; 280pp; English.
XX
CC   This invention describes novel isolated human secreted proteins and
CC   their encoding nucleic acid sequences. The products of the invention
CC   are useful for preventing, treating or ameliorating medical conditions
CC   e.g. by protein or gene therapy. Also pathological conditions can be
CC   diagnosed by determining the presence or amount of expression of
CC   the new polypeptides in a sample or by determining the presence or
CC   absence of mutations in the new polynucleotides. Specific uses are
CC   described for each of the 70 PNs, based on which tissues they are most
CC   highly expressed in, and include developing products for the diagnosis
CC   or treatment of cancer, tumours, neurodegenerative disorders,
CC   developmental abnormalities and foetal deficiencies, blood disorders,
CC   leukemias, diseases of the immune system, autoimmune diseases, hepatic
CC   and renal disease, lymphomas, inflammation, allergies, asthma, sepsis,
CC   diabetes, Alzheimer's and cognitive disorders, schizophrenia,
CC   osteoporosis, arthritis, psoriasis, digestive/endocrine disorders,
CC   infections and AIDS. The human secreted proteins of the invention are
CC   represented in AAY07744-Y07850 and the encoding nucleic acids are
CC   represented in AAX37369-X37441.
XX
SQ   Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;


  Query Match             100.0%;  Score 12;  DB 20;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT  15
AAX37448
ID   AAX37448 standard; DNA; 12 BP.
XX
AC   AAX37448;
XX
DT   06-JUL-1999  (first entry)
XX
DE   NF-KappaB promoter element PCR primer 1.
XX
KW   Human; secreted protein; treatment; prevention; protein therapy; AIDS;
KW   gene therapy; diagnosis; cancer; tumour; neurodegenerative disorder;
KW   developmental abnormality; fetal deficiency; blood disorder; leukemia;
KW   immune system disease; autoimmune disease; hepatic disease; lymphoma;
KW   renal disease; inflammation; allergy; Alzheimer's disease; schizophrenia;
KW   cognitive disorder; prostate disease; skeletal; cardiac; muscle disorder;
KW   pulmonary disorder; transplant rejection; osteoclast; osteoporosis;
KW   arthritis; malignancy; digestive; endocrine; infection; promoter;
KW   NF-KappaB; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO9918208-A1.
XX
PD   15-APR-1999.
XX
PF   01-OCT-1998;   98WO-US20775.
XX
PR   02-OCT-1997;   97US-0060884.
PR   02-OCT-1997;   97US-0060833.
PR   02-OCT-1997;   97US-0060836.
PR   02-OCT-1997;   97US-0060837.
PR   02-OCT-1997;   97US-0060838.
PR   02-OCT-1997;   97US-0060839.
PR   02-OCT-1997;   97US-0060843.
PR   02-OCT-1997;   97US-0060862.
```

PR 02-OCT-1997; 97US-0060866.
PR 02-OCT-1997; 97US-0060874.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Carter KC, Duan DR, Endress GA, Feng P, Ferrie AM;
PI Florence KA, Greene JM, Janat F, Lafleur DW, Ni J;
PI Rosen CA, Ruben SM, Shi Y, Young P, Yu G;
XX
DR WPI; 1999-264022/22.
XX
PT New isolated human genes and the secreted polypeptides they encode
XX
PS Example 16; Page 198; 368pp; English.
XX
CC This invention describes novel isolated human genes and the secreted
CC proteins they encode. The products of the invention are useful for
CC preventing, treating or ameliorating medical conditions, e.g. by protein
CC or gene therapy. Also pathological conditions can be diagnosed by
CC determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 101 Polynucleotides, based
CC on which tissues they are most highly expressed in, and include
CC developing products for the diagnosis or treatment of cancer, tumours,
CC neurodegenerative disorders, developmental abnormalities and fetal
CC deficiencies, blood disorders, leukemias, diseases of the immune system,
CC autoimmune diseases, hepatic and renal disease, lymphomas, inflammation,
CC allergies, Alzheimer's and cognitive disorders, schizophrenia, prostate
CC disease, skeletal or cardiac muscle disorders, pulmonary disorders,
CC transplant rejection, disorders involving osteoclasts such as
CC osteoporosis, arthritis or malignancies, digestive/endocrine disorders,
CC infections and AIDS. The human secreted proteins of the invention are
CC represented in AAY07852-Y07993 and the encoding nucleic acids are
CC represented in AAX37451-X37552.
XX
SQ Sequence 12 BP; 1 A; 4 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 12; DB 20; Length 12;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ggggactttccc 12
||||||||||||
Db 1 ggggactttccc 12

Search completed: September 22, 2002, 13:26:07
Job time: 4253 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 11:53:49 ; Search time 45.5 Seconds
(without alignments)
64.782 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggactttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	12	100.0	12	2	US-08-723-052-1	Sequence 1, Appli
	2	12	100.0	12	3	US-09-106-182-21	Sequence 21, Appl
	3	12	100.0	12	3	US-09-274-625-1	Sequence 1, Appli
	4	12	100.0	12	3	US-09-095-485-2	Sequence 2, Appli
	5	12	100.0	12	3	US-09-274-624-1	Sequence 1, Appli
	6	12	100.0	12	4	US-09-400-322-1	Sequence 1, Appli
	7	12	100.0	12	4	US-09-227-357-8	Sequence 8, Appli
	8	12	100.0	12	4	US-09-724-594-1	Sequence 1, Appli
	9	12	100.0	22	2	US-08-632-275-3	Sequence 3, Appli
	10	12	100.0	22	3	US-09-097-929-3	Sequence 3, Appli
	11	12	100.0	22	3	US-08-664-173A-1	Sequence 1, Appli
	12	12	100.0	22	3	US-08-797-696-1	Sequence 1, Appli
	13	12	100.0	22	3	US-09-037-712-2	Sequence 2, Appli
	14	12	100.0	22	4	US-09-157-808-1	Sequence 1, Appli
c	15	12	100.0	22	4	US-09-157-808-2	Sequence 2, Appli
	16	12	100.0	22	5	PCT-US94-05659-15	Sequence 15, Appl
	17	12	100.0	73	3	US-09-106-182-22	Sequence 22, Appl
	18	12	100.0	73	4	US-09-227-357-9	Sequence 9, Appli
	19	12	100.0	256	3	US-09-106-182-24	Sequence 24, Appl
	20	12	100.0	256	4	US-09-227-357-10	Sequence 10, Appl
c	21	12	100.0	423	1	US-08-253-155A-70	Sequence 70, Appl
c	22	12	100.0	944	4	US-09-386-493-4	Sequence 4, Appli
	23	12	100.0	1589	1	US-07-971-092-1	Sequence 1, Appli
	24	12	100.0	1611	6	5198342-1	Patent No. 5198342
	25	12	100.0	2638	4	US-09-228-986-8	Sequence 8, Appli
c	26	12	100.0	3060	2	US-08-560-398-1	Sequence 1, Appli
c	27	12	100.0	3946	3	US-09-083-351-1	Sequence 1, Appli
c	28	12	100.0	3946	4	US-09-083-352-1	Sequence 1, Appli
	29	12	100.0	9511	1	US-07-925-695-6	Sequence 6, Appli
	30	12	100.0	9511	1	US-07-925-695-7	Sequence 7, Appli
c	31	11	91.7	11	1	US-07-768-437-9	Sequence 9, Appli
	32	11	91.7	13	2	US-08-353-476-2	Sequence 2, Appli
	33	11	91.7	13	2	US-08-353-476-3	Sequence 3, Appli
	34	11	91.7	13	3	US-08-646-789A-16	Sequence 16, Appl
	35	11	91.7	13	3	US-08-646-789A-49	Sequence 49, Appl
	36	11	91.7	14	3	US-08-646-789A-36	Sequence 36, Appl
c	37	11	91.7	14	3	US-08-646-789A-92	Sequence 92, Appl
	38	11	91.7	15	2	US-08-353-476-4	Sequence 4, Appli
c	39	11	91.7	17	1	US-07-768-437-8	Sequence 8, Appli
c	40	11	91.7	20	2	US-08-850-993-3	Sequence 3, Appli
	41	11	91.7	21	4	US-09-021-247-6	Sequence 6, Appli
	42	11	91.7	23	3	US-08-353-765-1	Sequence 1, Appli
	43	11	91.7	24	5	PCT-US92-10792-7	Sequence 7, Appli
c	44	11	91.7	25	4	US-08-930-500-4	Sequence 4, Appli
c	45	11	91.7	25	4	US-08-930-500-5	Sequence 5, Appli

ALIGNMENTS

```
RESULT   1
US-08-723-052-1
; Sequence 1, Application US/08723052
; Patent No. 5922757
;  GENERAL INFORMATION:
;    APPLICANT:  Chojkier, Mario
;    APPLICANT:  Carson, Dennis
;    TITLE OF INVENTION:  TREATMENT AND PREVENTION OF HEPATIC DISORDERS
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/723,052
;      FILING DATE:
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Smith, Christopher J.
;      REGISTRATION NUMBER:  40,179
;      REFERENCE/DOCKET NUMBER:  UCSD-02424
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415/705-8410
;      TELEFAX:  415/397-8338
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-723-052-1


  Query Match           100.0%;  Score 12;  DB 2;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 GGGGACTTTCCC 12
```

```
RESULT   2
US-09-106-182-21
; Sequence 21, Application US/09106182
; Patent No. 6046035
;  GENERAL INFORMATION:
;    APPLICANT:  Shi, Yanggu
;    APPLICANT:  Ruben, Steve
;    TITLE OF INVENTION:  Cardiotrophin-Like Cytokine
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Human Genome Sciences, Inc
;      STREET:  9410 Key West Ave
;      CITY:  Rockville
;      STATE:  MD
;      COUNTRY:  US
;      ZIP:  20850
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/106,182
;      FILING DATE:  Herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/051,053
;      FILING DATE:  30-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Brookes, A. Anders
;      REGISTRATION NUMBER:  36,373
;      REFERENCE/DOCKET NUMBER:  PF385
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  301-309-8504
;      TELEFAX:  301-309-8439
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-106-182-21


  Query Match             100.0%;  Score 12;  DB 3;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 GGGGACTTTCCC 12


RESULT   3
US-09-274-625-1
; Sequence 1, Application US/09274625
; Patent No. 6075027
;  GENERAL INFORMATION:
;    APPLICANT:  Chojkier, Mario
;    TITLE OF INVENTION:  TREATMENT AND PREVENTION OF
;    TITLE OF INVENTION:  HEPATIC DISORDERS
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/274,625
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 09/274,624
;      FILING DATE:  23-MAR-1999
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MacKnight, Kamrin
;      REGISTRATION NUMBER:  38,230
;      REFERENCE/DOCKET NUMBER:  UCSD-03683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415/705-8410
;      TELEFAX:  415/397-8338
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-274-625-1


  Query Match             100.0%;  Score 12;  DB 3;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ggggactttccc 12
           ||||||||||||
Db       1 GGGGACTTTCCC 12


RESULT   4
US-09-095-485-2
; Sequence 2, Application US/09095485
; Patent No. 6127176
;  GENERAL INFORMATION:
;    APPLICANT:  Stark, George R.
;    APPLICANT:  Li, Xiaoxia
;    TITLE OF INVENTION:  Mutant Cell Lines Unresponsive to
;    TITLE OF INVENTION:  Interleukin 1
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Calfee, Halter & Griswold LLP
;      STREET:  1400 McDonald Investment Center, 800 Superior
;      STREET:  Avenue
;      CITY:  Cleveland
;      STATE:  Ohio
;      COUNTRY:  United States
;      ZIP:  44114
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/095,485
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Docherty, Pamela A.
;      REGISTRATION NUMBER:  40,591
;      REFERENCE/DOCKET NUMBER:  23114/04028
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (216) 622 8416
;      TELEFAX:  (216) 241 0816
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
```

```
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-095-485-2


  Query Match             100.0%;  Score 12;  DB 3;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   5
US-09-274-624-1
; Sequence 1, Application US/09274624
; Patent No. 6147123
;  GENERAL INFORMATION:
;    APPLICANT:  Chojkier, Mario
;    TITLE OF INVENTION:  TREATMENT AND PREVENTION OF
;    TITLE OF INVENTION:  HEPATIC DISORDERS
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MEDLEN & CARROLL, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/274,624
;      FILING DATE:  23-MAR-1999
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MacKnight, Kamrin
;      REGISTRATION NUMBER:  38,230
;      REFERENCE/DOCKET NUMBER:  UCSD-03683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415/705-8410
;      TELEFAX:  415/397-8338
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-274-624-1


  Query Match             100.0%;  Score 12;  DB 3;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   6
US-09-400-322-1
; Sequence 1, Application US/09400322
; Patent No. 6218437
; GENERAL INFORMATION:
;  APPLICANT: Chojkier, Mario
;  TITLE OF INVENTION: TREATMENT AND PREVENTION OF HEPATIC DISORDERS
;  FILE REFERENCE: UCSD-03831
;  CURRENT APPLICATION NUMBER: US/09/400,322
;  CURRENT FILING DATE: 1999-09-21
;  EARLIER APPLICATION NUMBER: 08/723,052
;  EARLIER FILING DATE: 1996-09-30
;  EARLIER APPLICATION NUMBER: 09/274,624
;  EARLIER FILING DATE: 1999-03-23
;  EARLIER APPLICATION NUMBER: 09/274,625
;  EARLIER FILING DATE: 1999-03-23
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-09-400-322-1


  Query Match             100.0%;  Score 12;  DB 4;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   7
US-09-227-357-8
; Sequence 8, Application US/09227357
; Patent No. 6342581
; GENERAL INFORMATION:
;  APPLICANT: Fischer et al.
;  TITLE OF INVENTION: 123 Human Secreted Proteins
;  FILE REFERENCE: PZ010P1
;  CURRENT APPLICATION NUMBER: US/09/227,357
;  CURRENT FILING DATE: 1999-01-08
;  EARLIER APPLICATION NUMBER: PCT/US98/13684
;  EARLIER FILING DATE: 1998-07-07
;  EARLIER APPLICATION NUMBER: 60/051,926
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/052,793
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,925
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,929
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/052,803
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/052,732
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,931
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,932
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,916
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,930
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,918
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,920
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/052,733
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/052,795
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,919
```

```
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/051,928
;  EARLIER FILING DATE: 1997-07-08
;  EARLIER APPLICATION NUMBER: 60/055,722
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,723
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,948
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,949
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,953
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,950
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,947
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,964
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/056,360
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,684
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,984
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/055,954
;  EARLIER FILING DATE: 1997-08-18
;  EARLIER APPLICATION NUMBER: 60/058,785
;  EARLIER FILING DATE: 1997-09-12
;  EARLIER APPLICATION NUMBER: 60/058,664
;  EARLIER FILING DATE: 1997-09-12
;  EARLIER APPLICATION NUMBER: 60/058,660
;  EARLIER FILING DATE: 1997-09-12
;  EARLIER APPLICATION NUMBER: 60/058,661
;  EARLIER FILING DATE: 1997-09-12
;  NUMBER OF SEQ ID NOS: 672
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-227-357-8


  Query Match           100.0%;  Score 12;  DB 4;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   8
US-09-724-594-1
; Sequence 1, Application US/09724594
; Patent No. 6348493
; GENERAL INFORMATION:
;  APPLICANT: Chojkier, Mario
;  TITLE OF INVENTION: TREATMENT AND PREVENTION OF HEPATIC DISORDERS
;  FILE REFERENCE: UCSD-03831
;  CURRENT APPLICATION NUMBER: US/09/724,594
;  CURRENT FILING DATE:  2000-11-28
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/400,322
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-09-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/274,624
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/274,625
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-23
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 12
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-09-724-594-1


  Query Match           100.0%;  Score 12;  DB 4;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 40;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 ggggactttccc 12


RESULT   9
US-08-632-275-3
; Sequence 3, Application US/08632275
; Patent No. 5840277
;  GENERAL INFORMATION:
;    APPLICANT:  Ghio, Andrew J.
;    APPLICANT:  Kennedy, Thomas P.
;    TITLE OF INVENTION:  Treatment of Chronic Pulmonary
;    TITLE OF INVENTION:  Inflamation
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Bell, Seltzer, Park & Gibson
;      STREET:  1211 East Morehead Street
;      CITY:  Charlotte
;      STATE:  No. 5840277th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/632,275
;      FILING DATE:  15-APR-1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/413,699
;      FILING DATE:  30-MAR-1995
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lipscomb, Ernest B.
;      REGISTRATION NUMBER:  24,733
;      REFERENCE/DOCKET NUMBER:  8751-5-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  704-331-6000
;      TELEFAX:  704-334-2014
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FRAGMENT TYPE:  linear
US-08-632-275-3


  Query Match           100.0%;  Score 12;  DB 2;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  10
```

```
US-09-097-929-3
; Sequence 3, Application US/09097929
; Patent No. 6024940
;  GENERAL INFORMATION:
;    APPLICANT:  Ghio, Andrew J.
;    APPLICANT:  Kennedy, Thomas P.
;    TITLE OF INVENTION:  Treatment of Chronic Pulmonary
;    TITLE OF INVENTION:  Inflamation
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Bell, Seltzer, Park & Gibson
;      STREET:  1211 East Morehead Street
;      CITY:  Charlotte
;      STATE:  No. 6024940th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/097,929
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/632,275
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lipscomb, Ernest B.
;      REGISTRATION NUMBER:  24,733
;      REFERENCE/DOCKET NUMBER:  8751-5-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  704-331-6000
;      TELEFAX:  704-334-2014
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FRAGMENT TYPE:  linear
US-09-097-929-3


  Query Match             100.0%;  Score 12;  DB 3;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  11
US-08-664-173A-1
; Sequence 1, Application US/08664173A
; Patent No. 6090938
;  GENERAL INFORMATION:
;    APPLICANT:  Wakshull, Eric
;    APPLICANT:  Mackin, William M.
;    APPLICANT:  Zimmerman, Janet
;    TITLE OF INVENTION:  Receptor for Underivatized, Aqueous
;    TITLE OF INVENTION:  Soluble B (1-3)-Glucan
;    NUMBER OF SEQUENCES:  1
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  US
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/664,173A
;      FILING DATE:  14-JUN-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/637,934
;      FILING DATE:  01-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Carroll, Alice O.
;      REGISTRATION NUMBER:  33,542
;      REFERENCE/DOCKET NUMBER:  ABY95-06A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-664-173A-1


  Query Match             100.0%;  Score 12;  DB 3;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  12
US-08-797-696-1
; Sequence 1, Application US/08797696
; Patent No. 6110692
;  GENERAL INFORMATION:
;    APPLICANT:  Wakshull, Eric
;    APPLICANT:  Mackin, William M.
;    APPLICANT:  Zimmerman, Janet
;    TITLE OF INVENTION:  Receptor for Underivatized, Aqueous
;    TITLE OF INVENTION:  Soluble B (1-3)-Glucan
;    NUMBER OF SEQUENCES:  1
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  US
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/797,696
;      FILING DATE:  31-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/664,173
;      FILING DATE:  14-JUN-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/637,934
;      FILING DATE:  01-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Carroll, Alice O.
;      REGISTRATION NUMBER:  33,542
```

```
;      REFERENCE/DOCKET NUMBER:  ABY95-06A2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-797-696-1


  Query Match           100.0%;  Score 12;  DB 3;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  13
US-09-037-712-2
; Sequence 2, Application US/09037712
; Patent No. 6123943
;  GENERAL INFORMATION:
;    APPLICANT:  BABA, Masanori
;    APPLICANT:  ONO, Minoru
;    TITLE OF INVENTION:  NF- B ACTIVITY INHIBITOR
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
;      STREET:  2100 Pennsylvania Avenue, N.W.
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20037-3202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/037,712
;      FILING DATE:  10-MAR-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  JAHNS, Kristina M.
;      REGISTRATION NUMBER:  41,092
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 293-7060
;      TELEFAX:  (202) 293-7860
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-037-712-2


  Query Match           100.0%;  Score 12;  DB 3;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  14
US-09-157-808-1
; Sequence 1, Application US/09157808
; Patent No. 6312896
; GENERAL INFORMATION:
;  APPLICANT: Heroux, Jeffrey A
;  APPLICANT: Kibbey, Maura C
;  APPLICANT: Kenten, John H
;  TITLE OF INVENTION: Assays for Measuring Nucleic Acid Binding Proteins and
;  TITLE OF INVENTION: Enzyme Activities
;  FILE REFERENCE: P09100US
;  CURRENT APPLICATION NUMBER: US/09/157,808
;  CURRENT FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_difference
;   LOCATION: (1)..(8)
;   OTHER INFORMATION: Nucleotides are linked by phophorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_difference
;   LOCATION: (16)..(22)
;   OTHER INFORMATION: Nucleotides are linked by phorothioate linkages
;   FEATURE:
;   NAME/KEY: misc_difference
;   LOCATION: (1)
;   OTHER INFORMATION: 5'-Labeled with ruthenium tris-bipyridyl
;   FEATURE:
;   NAME/KEY: misc_difference
;   LOCATION: (22)
;   OTHER INFORMATION: 3'-Labeled with biotin
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Artificial
;   OTHER INFORMATION: sequence containing a consensus sequence for human
;   OTHER INFORMATION: NFkB
US-09-157-808-1


  Query Match           100.0%;  Score 12;  DB 4;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 43;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 ggggactttccc 18


RESULT  15
US-09-157-808-2/c
; Sequence 2, Application US/09157808
; Patent No. 6312896
; GENERAL INFORMATION:
;  APPLICANT: Heroux, Jeffrey A
;  APPLICANT: Kibbey, Maura C
;  APPLICANT: Kenten, John H
;  TITLE OF INVENTION: Assays for Measuring Nucleic Acid Binding Proteins and
;  TITLE OF INVENTION: Enzyme Activities
;  FILE REFERENCE: P09100US
;  CURRENT APPLICATION NUMBER: US/09/157,808
;  CURRENT FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Artificial
;   OTHER INFORMATION: sequence containing consensus sequence for human
;   OTHER INFORMATION: NFkB
```

US-09-157-808-2

Query Match 100.0%; Score 12; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 ggggactttccc 12
           ||||||||||||
Db      16 GGGGACTTTCCC 5
```

Search completed: September 22, 2002, 13:22:12
Job time: 5303 sec

09/724,666

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 22, 2002, 11:30:20 ; Search time 1872.1 Seconds
(without alignments)
134.137 Million cell updates/sec

Title: US-09-400-322-1
Perfect score: 12
Sequence: 1 ggggactttccc 12

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 3595312

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htgo_inv:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	12	100.0	12	6	AR098339	AR098339 Sequence
2	12	100.0	12	6	AR111721	AR111721 Sequence
3	12	100.0	12	6	AR141741	AR141741 Sequence
4	12	100.0	12	6	AR146394	AR146394 Sequence
5	12	100.0	22	6	AR059258	AR059258 Sequence
6	12	100.0	22	6	AR107990	AR107990 Sequence
7	12	100.0	22	6	AR176711	AR176711 Sequence
c 8	12	100.0	22	6	AR176712	AR176712 Sequence
9	12	100.0	22	6	AX019403	AX019403 Sequence
10	12	100.0	22	6	AX195273	AX195273 Sequence
11	12	100.0	22	6	AX299025	AX299025 Sequence
12	12	100.0	116	6	AX189780	AX189780 Sequence
13	12	100.0	116	6	AX189781	AX189781 Sequence
14	12	100.0	199	6	AX189782	AX189782 Sequence
c 15	12	100.0	268	9	HUMRRTH	M29212 Human Th RN
c 16	12	100.0	275	10	RATSR72R	J05014 Rat gene fo
c 17	12	100.0	277	9	HSA399934	AJ399934 Homo sapi
c 18	12	100.0	300	9	HS21E8R	Z65152 H.sapiens C
19	12	100.0	336	11	G17247	G17247 SHGC-5780 P
c 20	12	100.0	354	9	HSZ85094	Z85094 H.sapiens I
21	12	100.0	372	9	AB071192S1	AB071192 Homo sapi
22	12	100.0	372	9	HSCD89EX3	X87769 H.sapiens C
c 23	12	100.0	372	9	HSZ85093	Z85093 H.sapiens I
24	12	100.0	380	4	SSZ97397	Z97397 Sus scrofa
25	12	100.0	387	6	AX302813	AX302813 Sequence
26	12	100.0	395	11	HS291WE5	Z51285 H.sapiens (
c 27	12	100.0	396	6	AX198652	AX198652 Sequence
c 28	12	100.0	396	6	AX209187	AX209187 Sequence
c 29	12	100.0	398	11	HSSTS2F5	X83387 H.sapiens S
30	12	100.0	417	10	AF104150	AF104150 Rattus ex
c 31	12	100.0	423	6	I76242	I76242 Sequence 70
32	12	100.0	471	9	AF305868	AF305868 Pan trogl
33	12	100.0	492	8	AF461579	AF461579 Unculture
34	12	100.0	540	9	D87856	D87856 Homo sapien
35	12	100.0	576	9	D87854	D87854 Homo sapien
36	12	100.0	576	9	S82919	S82919 CD89-IgA Fc
37	12	100.0	585	9	HSIGAFCR4	X92561 H.sapiens m
38	12	100.0	608	9	HSU43677	U43677 Human Fc al
c 39	12	100.0	613	9	HSA335319	AJ335319 Homo sapi
40	12	100.0	618	9	D87860	D87860 Homo sapien
41	12	100.0	654	9	D87858	D87858 Homo sapien
42	12	100.0	679	8	AF461581	AF461581 Unculture
43	12	100.0	679	8	AF461582	AF461582 Unculture
c 44	12	100.0	725	9	HSA330092	AJ330092 Homo sapi
45	12	100.0	754	9	D87857	D87857 Homo sapien

ALIGNMENTS

RESULT 1
AR098339
LOCUS AR098339 12 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6075027.
ACCESSION AR098339
VERSION AR098339.1 GI:12807596
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Chojkier,M. and Carson,D.
TITLE Treatment and prevention of hepatic disorders
JOURNAL Patent: US 6075027-A 1 13-JUN-2000;
FEATURES Location/Qualifiers
source 1. .12
/organism="unknown"
BASE COUNT 1 a 4 c 4 g 3 t
ORIGIN

Query Match 100.0%; Score 12; DB 6; Length 12;
Best Local Similarity 100.0%; Pred. No. 4.8e+03;

```
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   2
AR111721
LOCUS       AR111721                  12 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 2 from patent US 6127176.
ACCESSION   AR111721
VERSION     AR111721.1  GI:12828569
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Stark,G.R. and Li,X.
  TITLE     Mutant cell lines unresponsive to interleukin 1
  JOURNAL   Patent: US 6127176-A 2 03-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
BASE COUNT        1 a      4 c      4 g      3 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   3
AR141741
LOCUS       AR141741                  12 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 1 from patent US 6147123.
ACCESSION   AR141741
VERSION     AR141741.1  GI:15101257
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Chojkier,M. and Carson,D.
  TITLE     Treatment and prevention of hepatic disorders
  JOURNAL   Patent: US 6147123-A 1 14-NOV-2000;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
BASE COUNT        1 a      4 c      4 g      3 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   4
AR146394
LOCUS       AR146394                  12 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 1 from patent US 6218437.
ACCESSION   AR146394
VERSION     AR146394.1  GI:15109583
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Chojkier,M.
  TITLE     Treatment and prevention of hepatic disorders
  JOURNAL   Patent: US 6218437-A 1 17-APR-2001;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
BASE COUNT        1 a      4 c      4 g      3 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.8e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      1 GGGGACTTTCCC 12


RESULT   5
AR059258
LOCUS       AR059258                  22 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 3 from patent US 5840277.
ACCESSION   AR059258
VERSION     AR059258.1  GI:5985708
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Ghio,A.J. and Kennedy,T.P.
  TITLE     Treatment of chronic pulmonary inflammation
  JOURNAL   Patent: US 5840277-A 3 24-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT   6
AR107990
LOCUS       AR107990                  22 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 1 from patent US 6110692.
ACCESSION   AR107990
VERSION     AR107990.1  GI:12823477
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Wakshull,E., Mackin,W.M. and Zimmerman,J.
  TITLE     Receptor for underivatized aqueous soluble .beta.(1-3)-glucan
  JOURNAL   Patent: US 6110692-A 1 29-AUG-2000;
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN
```

```
  Query Match             100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT   7
AR176711
LOCUS       AR176711                  22 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 1 from patent US 6312896.
ACCESSION   AR176711
VERSION     AR176711.1  GI:17919066
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Heroux,J.A., Kibbey,M.C. and Kenten,J.H.
  TITLE     Assays for measuring nucleic acid binding proteins and enzyme
            activities
  JOURNAL   Patent: US 6312896-A 1 06-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT   8
AR176712/c
LOCUS       AR176712                  22 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 2 from patent US 6312896.
ACCESSION   AR176712
VERSION     AR176712.1  GI:17919067
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Heroux,J.A., Kibbey,M.C. and Kenten,J.H.
  TITLE     Assays for measuring nucleic acid binding proteins and enzyme
            activities
  JOURNAL   Patent: US 6312896-A 2 06-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="unknown"
BASE COUNT        5 a      8 c      5 g      4 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     16 GGGGACTTTCCC 5


RESULT   9
AX019403
LOCUS       AX019403                  22 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 19 from Patent WO9940187.
ACCESSION   AX019403
VERSION     AX019403.1  GI:10043373
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Abken,H.
  TITLE     Nucleic acids provided for modulating cellular activation
  JOURNAL   Patent: WO 9940187-A 19 12-AUG-1999;
            ABKEN HINRICH (DE)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="synthetische"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  10
AX195273
LOCUS       AX195273                  22 bp    DNA     linear   PAT 28-AUG-2001
DEFINITION  Sequence 9 from Patent WO0151671.
ACCESSION   AX195273
VERSION     AX195273.1  GI:15385824
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Mccarthy,J. and Cordell,B.
  TITLE     Methods for identifying inhibitors of neuronal degeneration
  JOURNAL   Patent: WO 0151671-A 9 19-JUL-2001;
            Scios Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="Synthetic Oligonucleotide"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN


  Query Match             100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  11
AX299025
LOCUS       AX299025                  22 bp    DNA     linear   PAT 26-NOV-2001
DEFINITION  Sequence 7 from Patent WO0183713.
ACCESSION   AX299025
VERSION     AX299025.1  GI:17129015
KEYWORDS    .
```

```
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (sites)
  AUTHORS   Robbins,P.D., Lu,L. and Giannoukakis,N.
  TITLE     The use of tolerogenic dendritic cells for enhancing tolerogenicity
            in a host and methods for making the same
  JOURNAL   Patent: WO 0183713-A 7 08-NOV-2001;
            UNIV PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="Synthesized nucleotide sequence"
BASE COUNT        4 a      5 c      8 g      5 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 22;
  Best Local Similarity  100.0%;  Pred. No. 4.5e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db      7 GGGGACTTTCCC 18


RESULT  12
AX189780
LOCUS       AX189780                116 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 11 from Patent WO0148187.
ACCESSION   AX189780
VERSION     AX189780.1  GI:15143151
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 116)
  AUTHORS   Webster,K.A.
  TITLE     A molecular switch for regulating mammalian gene expression
  JOURNAL   Patent: WO 0148187-A 11 05-JUL-2001;
            The University of Miami (US)
FEATURES             Location/Qualifiers
     source          1. .116
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"
BASE COUNT       22 a     35 c     37 g     22 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 116;
  Best Local Similarity  100.0%;  Pred. No. 3.9e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     23 GGGGACTTTCCC 34


RESULT  13
AX189781
LOCUS       AX189781                116 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 12 from Patent WO0148187.
ACCESSION   AX189781
VERSION     AX189781.1  GI:15143152
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 116)
  AUTHORS   Webster,K.A.
  TITLE     A molecular switch for regulating mammalian gene expression
  JOURNAL   Patent: WO 0148187-A 12 05-JUL-2001;
            The University of Miami (US)
FEATURES             Location/Qualifiers
     source          1. .116
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"
BASE COUNT       22 a     35 c     31 g     28 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 116;
  Best Local Similarity  100.0%;  Pred. No. 3.9e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db     23 GGGGACTTTCCC 34


RESULT  14
AX189782
LOCUS       AX189782                199 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 13 from Patent WO0148187.
ACCESSION   AX189782
VERSION     AX189782.1  GI:15143153
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 199)
  AUTHORS   Webster,K.A.
  TITLE     A molecular switch for regulating mammalian gene expression
  JOURNAL   Patent: WO 0148187-A 13 05-JUL-2001;
            The University of Miami (US)
FEATURES             Location/Qualifiers
     source          1. .199
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"
BASE COUNT       52 a     62 c     48 g     37 t
ORIGIN


  Query Match           100.0%;  Score 12;  DB 6;  Length 199;
  Best Local Similarity  100.0%;  Pred. No. 3.7e+03;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 ggggactttccc 12
          ||||||||||||
Db    185 GGGGACTTTCCC 196


RESULT  15
HUMRRTH/c
LOCUS       HUMRRTH                 268 bp ss-RNA     linear   PRI 27-APR-1993
DEFINITION  Human Th RNA, complete cds.
ACCESSION   M29212
VERSION     M29212.1  GI:174915
KEYWORDS    ribonucleoprotein.
SOURCE      Homo sapiens serum scRNA.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 268)
  AUTHORS   Gold,H.A., Topper,J.N., Clayton,D.A. and Craft,J.
  TITLE     The RNA processing enzyme RNase MRP is identical to the Th RNP and
            related to RNase P
  JOURNAL   Science 245, 1377-1380 (1989)
  MEDLINE   89388247
FEATURES             Location/Qualifiers
     source          1. .268
                     /organism="Homo sapiens"
```

```
                     /db_xref="taxon:9606"
                     /tissue_type="serum"
     misc_RNA        1. .268
                     /note="Th RNA"
BASE COUNT       47 a      93 c      75 g      53 t
ORIGIN
```

Query Match 100.0%; Score 12; DB 9; Length 268;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 ggggactttccc 12
           ||||||||||||
Db      78 GGGGACTTTCCC 67
```

Search completed: September 22, 2002, 13:21:08
Job time: 6648 sec

THIS PAGE BLANK (USPTO)